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Abstract
Exome sequencing is the most advanced standard-of-care genetic test for people with suspected
Mendelian disorders. Yet, the diagnostic rate of exome sequencing is only 31%. RNA sequencing (RNAseq) is a promising molecular test for detecting potentially pathogenic changes in RNA splicing as part of
obtaining a molecular diagnosis. In this dissertation, I develop new computational tools and perform
analyses towards improving how we detect these potentially pathogenic changes in RNA splicing with the
goal of improving the molecular diagnostic rate. First, in Chapter 1, I review background on how we
diagnose patients and how RNA splicing and RNA-seq could be used to improve this process. Then, in
Chapter 2, I describe my contributions to MAJIQ v2 as methodology to study RNA splicing from large and
heterogeneous RNA-seq datasets. Afterwards, I use MAJIQ v2 in Chapter 3 to evaluate how tissuespecific expression and splicing affects what clinically-relevant splicing changes we can identify from
clinically-accessible tissues. Then, in Chapter 4, I describe the limitations of MAJIQ v2 for our approach to
detect splicing aberrations and the development and evaluation of MAJIQ v3 to address these challenges.
With MAJIQ v3, I develop MAJIQ-CLIN in Chapter 5 to identify and prioritize splicing aberrations in patient
RNA-seq data and compare our method to previous approaches. Finally, in Chapter 6, I discuss overall
conclusions for the work and exciting areas for future work. Together, the work in this dissertation pushes
forward how we can study and use RNA-seq to improve the diagnostic rate of patients with suspected
Mendelian disorders.
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ABSTRACT
IMPROVING MOLECULAR DIAGNOSIS OF SUSPECTED MENDELIAN DISORDERS WITH
RNA SPLICING ANALYSIS
Joseph K. Aicher
Yoseph Barash
Elizabeth J. Bhoj
Exome sequencing is the most advanced standard-of-care genetic test for people with suspected
Mendelian disorders. Yet, the diagnostic rate of exome sequencing is only 31%. RNA sequencing
(RNA-seq) is a promising molecular test for detecting potentially pathogenic changes in RNA
splicing as part of obtaining a molecular diagnosis. In this dissertation, I develop new computational tools and perform analyses towards improving how we detect these potentially pathogenic
changes in RNA splicing with the goal of improving the molecular diagnostic rate. First, in
Chapter 1, I review background on how we diagnose patients and how RNA splicing and RNA-seq
could be used to improve this process. Then, in Chapter 2, I describe my contributions to MAJIQ
v2 as methodology to study RNA splicing from large and heterogeneous RNA-seq datasets.
Afterwards, I use MAJIQ v2 in Chapter 3 to evaluate how tissue-specific expression and splicing
affects what clinically-relevant splicing changes we can identify from clinically-accessible tissues.
Then, in Chapter 4, I describe the limitations of MAJIQ v2 for our approach to detect splicing
aberrations and the development and evaluation of MAJIQ v3 to address these challenges. With
MAJIQ v3, I develop MAJIQ-CLIN in Chapter 5 to identify and prioritize splicing aberrations in
patient RNA-seq data and compare our method to previous approaches. Finally, in Chapter 6, I
discuss overall conclusions for the work and exciting areas for future work. Together, the work in
this dissertation pushes forward how we can study and use RNA-seq to improve the diagnostic
rate of patients with suspected Mendelian disorders.
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CHAPTER 1
Introduction
1.1. Challenges in molecular diagnosis of Mendelian disorders
Exome sequencing is the most advanced standard-of-care genetic test for patients with
suspected Mendelian disorders. The goal is to successfully determine a molecular diagnosis
for each patient by identifying the pathogenic genetic variant(s) causing disease. Clinically,
molecular diagnoses can lead to more accurate prognoses and improved clinical care for patients
and their families. Scientifically, molecular diagnoses also inform fundamental biological research
by suggesting novel genes and mechanisms in both normal development and disease pathogenesis.
Unfortunately, a significant challenge in clinical and molecular genetics is that we are unable to
provide a molecular diagnosis to most families of children tested with exome sequencing. Specifically, the molecular diagnostic rate of exome sequencing across various diagnostic laboratories
averages only around 31% (Clark et al., 2018; Yang et al., 2014; Farwell et al., 2015; Retterer
et al., 2016). Genome sequencing, where it has begun being implemented, has been reported to
improve upon this diagnostic rate by around 10-15% (Clark et al., 2018; Alfares et al., 2018;
Taylor et al., 2015). As a result, we are unable to provide a molecular diagnosis for the majority
of patients tested with either exome or genome sequencing.
Exome sequencing measures an individual’s personal genetic sequences at the exons
and adjacent intronic regions for nearly all known genes, typically identifying tens of thousands
of variants (Ross et al., 2020). In clinical practice, these variants must be prioritized by a
computational pipeline to generate a short list of candidate variants that can be manually
reviewed by genomic professionals. These pipelines rely on databases of known pathogenic
variants (e.g., HGMD (Stenson et al., 2003), ClinVar (Landrum et al., 2014)) and predictive
models of pathogenicity for new variants. To be useful for variant prioritization, predictive
models must be highly sensitive and specific to ensure that the few causal pathogenic variants
are scored highly versus the far more numerous benign variants. Clinical pipelines generally only
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evaluate nonsynonymous and canonical splice-site variants, for which such predictive models
exist. Although other intronic and synonymous exonic variants are known to cause disease, their
pathogenicity is challenging to predict (Frésard and Montgomery, 2018; Gloss and Dinger, 2018).
Consequently, existing clinical pipelines generally filter out such variants, resulting in missed
diagnoses.

1.2. RNA splicing defects as a mechanism for Mendelian disease
One key mechanism by which intronic and exonic variants can cause disease is by altering
RNA splicing (Scotti and Swanson, 2016; Wang and Cooper, 2007). RNA splicing is the process
by which different segments of pre-mRNA are selectively included or excluded and removed as
exons and introns to create a mature mRNA (from which proteins are translated) (Figure 1.1).
This process is highly regulated across developmental stages and tissues, with over 90% of
human genes undergoing alternative splicing, and is mediated by the spliceosome and numerous
RNA-binding proteins (RBPs) that recognize different conserved sequence elements. Variants in
these splice factors can thus alter splicing in trans, and intronic and exonic variants can alter
splicing in cis by changing the strength of existing sequence elements or introducing cryptic ones.
These different changes in splicing can alter protein function by inserting or removing part of
the mRNA transcript (Figure 1.1). Furthermore, they can sometimes cause a frameshift and/or
insertion of a premature termination codon, leading to loss of function. Such splicing-altering
variants are known to cause Mendelian disorders (e.g., familial dysautonomia, Crouzon syndrome,
etc.) and are associated with complex diseases such as Alzheimer’s disease and cancer (Scotti
and Swanson, 2016; Fenwick et al., 2014; Raj et al., 2018). It is estimated that 15-50% of
human pathogenic variants alter splicing, with the lower number attributed to splice-sites alone
and the higher number more challenging to pin down due to lack of appropriate data or tools
and inherent biases in disease-variant databases for splice-site mutations (see above). A recent
study suggests that these biases could cause existing clinical pipelines to miss the majority of
splice-disrupting variants; Cheung et al. (2019) performed a massively parallel splicing reporter
assay of 27,733 exonic and intronic variants in 2,198 human exons from ExAC and found that
variants in core splice-sites only accounted for 17% of splice-disrupting variants, with the majority
2

of splice-disrupting variants occurring outside of the extended splice region. Recent years have
seen a surge in splicing and isoform-specific focused therapeutics for rare genetic diseases such as
spinal muscular atrophy and familial dysautonomia, as well as cancer (Singh and Cooper, 2012;
Sinha et al., 2018; Seiler et al., 2018; Sotillo et al., 2015).
pre-mRNA splicing
pre-mRNA

splicing decisions

mature mRNA

Functional consequences:
- Δ protein sequence, localization
- premature termination codon
- frameshift
- etc.

Figure 1.1: Different precursor mRNA (pre-mRNA) splicing decisions can have significant,
potentially pathogenic, functional consequences.
Broadly, there are two approaches by which we can improve identification of variants
causing potentially disease-causing alterations to RNA splicing: (1, DNA-first) better algorithms
for predicting defects in RNA splicing from genetic sequence and (2, RNA-first) orthogonal
approaches for directly measuring potentially disease-causing alterations to RNA splicing from
patient RNA and matching back to genetic variants.

1.3. Algorithms to predict deleterious splicing changes
Given the importance of splicing and identifying pathogenic variants in general, many
algorithms have been developed in recent years for variant annotation and prediction (see
Table 1.1). Many algorithms (e.g., GWAVA, M-CAP, etc.) produce a score that can be used as
a pathogenicity score for general variants. This score is sometimes trained directly on known
pathogenic variants or indirectly using information about conservation/other annotations. While
effective, they are not tailored specifically for splicing defects. S-CAP similarly produces a
pathogenicity score but specifically focuses on predicting pathogenicity for variants that do not
3

Table 1.1: Algorithms for DNA-first splicing variant prioritization.
Model

Citation

Type of algorithm

GWAVA
CADD
M-CAP
EIGEN
LINSIGHT
S-CAP
HAL
SPIDEX

Ritchie et al. (2014)
Kircher et al. (2014)
Jagadeesh et al. (2016)
Ionita-Laza et al. (2016)
Huang et al. (2017)
Jagadeesh et al. (2018)
Rosenberg et al. (2015)
Xiong et al. (2015)
Jha et al. (2017)
Cheng et al. (2019)
Jaganathan et al. (2019)
Cheng et al. (2021)

Pathogenicity scoring
Pathogenicity scoring
Pathogenicity scoring
Pathogenicity scoring
Pathogenicity scoring
Pathogenicity scoring
Synthetic minigene
Splicing code
Splicing code
Splicing code
Splicing code
Splicing code

MMSplice
SpliceAI
MTSplice

directly affect protein-coding sequence using splicing-related features. Other algorithms (e.g.,
HAL) use synthetic libraries but lack appropriate tissue context, and most lack mechanistic
interpretation. Splicing code models offer great potential for variant prioritization as these
can predict condition-specific splicing changes and offer mechanistic interpretation to diseaseassociated variants; however, these models have not yet been trained on genetic variants.
Benchmarks for these different algorithms often apply different metrics or datasets, hindering the
identification of the best algorithms for incorporation into clinical diagnosis pipelines. Completed
and ongoing works I contributed to during my PhD are aimed to improve such methods (Jha
et al., 2020).

1.4. Detection and quantification of RNA splicing using RNA-seq
However, the focus of this dissertation is directly measuring potentially disease-causing
alterations to RNA splicing from patient RNA and matching back to genetic variants (the
RNA-first approach). Clinical RNA-seq is one approach by which laboratories can identify splicing
aberrations among other transcriptomic variations such as gene-expression outliers, allele-specific
expression, and gene fusions. Indeed, previous work in several labs have demonstrated that
RNA-seq can enable genetic diagnosis in patients previously unsolved by exome or genome
sequencing (Cummings et al., 2017; Kremer et al., 2017; Gonorazky et al., 2019; Frésard et al.,
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2019; Mertes et al., 2021; Jenkinson et al., 2020; Murdock et al., 2021).
RNA-seq describes a variety of methods which measure sequence from a given sample of
RNA. The resulting sequences provide information about the presence and relative abundance
of specific genomic features (e.g., genes, isoforms, splice sites, etc.) corresponding to observed
sequences. Most commonly, input RNA is first enriched for mRNA, followed by reverse transcription to cDNA, and then sequencing with “short-reads” with Illumina technology (Stark et al.,
2019). This approach is relatively inexpensive and yields short (∼200bp) cDNA fragments which
are sequenced with high accuracy. In contrast, alternative technology (e.g., PacBio, Oxford
Nanopore) has more recently enabled sequencing of much longer cDNA (or direct sequencing of
RNA) at lengths over 1-10kb, but currently with lower (but increasing) accuracy and throughput
(Amarasinghe et al., 2020; Stark et al., 2019).
The resulting sequences can be used to quantify changes in gene isoform usage. Methods
to quantify these changes can be divided broadly between methods that aim to quantify whole
isoforms and those that quantify localized alternative splicing (AS) “events” within a gene.
While quantifying all gene isoforms accurately across diverse conditions can be regarded as the
grand challenge of transcriptomics, achieving this goal remains open due to several limiting
factors. In the case of long reads technology, these factors include high error rate and high
costs which do not allow researchers to capture enough reads from all isoforms. In the case
of the more commonly used short reads technology, these limiting factors include the sparsity
of reads, their positional bias, and the fact that reads usually cannot be assigned to a unique
isoform. In addition, the composition of isoforms in a sample is typically unknown, requiring
further inference of the existing isoforms or making simplifying assumptions such as a known
transcriptome. These issues have led many researchers to focus on local AS “events” which
can be more easily and accurately quantified from RNA-seq. AS events are quantified in terms
of percent spliced in (PSI, denoted by Ψ), which is the relative ratio of isoforms including a
specific splicing junction or retained intron. Traditionally, AS events have been studied only
for a restricted set of the most common “types” (e.g., cassette exons). In a previous study,
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Vaquero-Garcia et al. (2016) extended this set of AS event types using the formulation of local
splicing variations (LSVs) and introduced MAJIQ as a software package for studying such LSVs.
LSVs, which can be defined as splits in a gene splicegraph coming into or from a reference exon,
allow researchers to capture not only previously defined AS types but also much more complex
variations involving more than two alternative junctions. Furthermore, the LSV formulation,
and similar definitions of local AS events suggested in subsequent works, also help incorporate
and quantify unannotated (novel) splice junctions. Previous work comparing splicing across
mouse tissues has shown that accounting for complex and novel variations results in an over 30%
increase of detected differentially spliced events while maintaining the same level of reproducibility
and experimental validation rates (Vaquero-Garcia et al., 2016). Importantly, capturing such
unannotated splice variations is of particular importance for the study of disease such as cancer
and neurodegeneration which often involve aberrant splicing.
Recent works have applied RNA-seq to identify splicing and other transcriptomic aberrations in RNA-seq data from patients with suspected Mendelian disorders (Cummings et al.,
2017; Kremer et al., 2017; Gonorazky et al., 2019; Frésard et al., 2019; Mertes et al., 2021;
Jenkinson et al., 2020; Murdock et al., 2021). In this setting, the goal is to identify changes that
are unusual (i.e., outliers in the patient vs other samples) and subsequently correlate them with
the patient’s clinical phenotype and genetic variants. Focusing on splicing aberrations, some
of these methods look at evidence of a novel spliced junction regardless of relative inclusion
(Cummings et al., 2017; Gonorazky et al., 2019), while others quantify relative inclusion (e.g.,
PSI, etc.) (Kremer et al., 2017; Frésard et al., 2019; Mertes et al., 2021; Jenkinson et al., 2020;
Murdock et al., 2021). They compare this evidence to a large control set of either external
RNA-seq experiments (e.g., GTEx (GTEx Consortium et al., 2017)) or the other patient samples
(leave-one-out), assuming that they have different splicing aberrations as the cause of their
diseases. Some methods further model and correct for unobserved causes of sample covariation
that could cause spurious outliers (Frésard et al., 2019; Mertes et al., 2021).
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1.5. Gaps in knowledge
The focus of my dissertation research is to improve the molecular diagnostic rate for
patients with suspected Mendelian disorders by identifying splicing aberrations from RNA-seq.
Identifying these splicing aberrations from RNA-seq first requires an accurate and efficient
approach for identifying and quantifying splicing changes in large (and often heterogeneous) RNAseq datasets. Furthermore, tissue-specific expression and splicing mean that splicing aberrations
in the clinically-relevant tissues (e.g., brain) will not always be measurable in the tissues which are
clinically-available (e.g., fibroblasts). Finally, efficiently identifying splicing aberrations requires
new methodology for identifying relevant novel changes in splicing events and quantifications
and correcting for sample covariation due to known as well as unknown confounders.
In Chapter 2, I describe the new algorithms and performance comparisons I contributed
to MAJIQ v2 which address challenges posed by large and heterogeneous RNA-seq datasets. In
Chapter 3, I use MAJIQ v2 to understand the limitations of clinically-accessible tissues (CATs)
for representing changes in non-CATs, informing which potentially pathogenic splicing changes
we can hope to measure and which tissues we should prefer to sample in the clinical setting. In
Chapter 4, I describe additional limitations we identified in MAJIQ v2 we needed to address to
identify splicing aberrations in suspected Mendelian disorders, leading to MAJIQ v3. In Chapter 5,
I describe the approach we developed for identifying splicing aberrations and comparisons to
previous methodologies on patient data.
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CHAPTER 2
RNA splicing analysis using heterogeneous and large RNA-seq datasets
2.1. Introduction
Despite previous demonstrations of MAJIQ’s utility for analyzing AS (Vaquero-Garcia
et al., 2016; Norton et al., 2018), we found MAJIQ along with many commonly used methods
for AS events quantification to be ill-suited for handling heterogeneous and large RNA-seq
datasets, such as GTEx and ENCODE. Datasets may involve anywhere from just a few to many
thousands of samples each, and are typically heterogeneous as they often do not represent
biological or technical replicates. The consequent increased splicing variability, illustrated in
Figure 2.1a-b, can be the result of a multitude of factors, both experimental/technical (e.g.,
difference in sequencing machine), and biological (e.g., gender, age). While some confounding
factors may be corrected with appropriate methods (Slaff et al., 2021), fully removing the
observed variability in such data is unlikely and may also over-constrain the data, thus leading
to a loss of true biological signal. These datasets pose several algorithmic, computational, and
visualization challenges. First, the assumption of a shared PSI per LSV junction in a group, used
by methods such as MAJIQ and LeafCutter, is violated in such data even when handling only
a small dataset with few samples, leading to a potential increase in false positives and loss of
power. Second, algorithms need to not only scale to thousands of samples efficiently but also to
allow incrementally adding new samples as more data is acquired, and to support multiple group
comparisons (e.g. multiple tissue comparisons across GTEx). Third, the increased complexity
of the data requires efficient representation. Such efficient representation would allow users to
capture the many unannotated splicing variations in the data, while at the same time simplifying
its representation and quantification. Such simplification will allow filtering of lowly used splice
junctions while also detecting possibly new sub-types of significant variations. Finally, efficient
and user-friendly visualization is required to probe multiple sample groups as well as individual
samples.
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Figure 2.1: MAJIQ efficiently and accurately models, quantifies, and visualizes RNA splicing
from large and complex RNA-seq datasets. (cont.)
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Figure 2.1: (cont.) (a) The number of identified distinct unannotated de novo junctions increases
with larger subsets of different tissues from GTEx. Lines show the median over 30 randomly
selected permutations over experiments in each subset, confidence bands show the 5th to 95th
percentiles over permutations of samples per tissue. (b) The number of genes with at least one
junction where the difference between the 95th percentile and 5th percentile of PSI exceeds a
given value for different tissues from GTEx (same tissues/colors as in Fig. 1a). Dashed vertical
line indicates how many genes have a difference in PSI exceeding 20%. (c) MAJIQ combines
annotated transcript databases and coverage from input RNA-seq experiments to build a model
of each gene as a collection of exons connected by annotated and de novo junctions and retained
introns (splicegraph). Junctions and retained introns sharing the same source or target exon
form local splicing variations (LSVs). MAJIQ quantifies the relative inclusion of junctions and
retained introns in each LSV in terms of percent spliced in (PSI, Ψ) and provides VOILA to
make interactive visualizations of splicing quantifications with respect to each gene’s splicegraph
and LSV structures. MAJIQ v2 introduces an incremental build, which allows RNA-seq coverage
to be read from BAM files only once to a coverage file (SJ), accelerating subsequent builds
with different experiments. MAJIQ v2 introduces a simplifier, which can be used to reduce
splicegraph/LSV complexity by ignoring lowly used junctions and retained introns. MAJIQ
v2 introduces a new mode for quantification, HET, which compares PSI differences between
populations of independent RNA-seq experiments and accounts for variable uncertainty per
experiment. MAJIQ v2 introduces the modulizer, which allows performing analysis relative to
non-overlapping splicing modules rather than LSVs.

To address these challenges, we developed an array of tools and algorithms included in
the MAJIQ v2 package. In this chapter, I describe the MAJIQ v2 algorithms and my contributions
to this work, including the nonparametric statistical tests for differential splicing (MAJIQ HET),
the incremental splicegraph builder, and the MAJIQ v2 algorithm for quantifying intron retention.

2.2. Results
2.2.1. The MAJIQ v2 splicing analysis pipeline
To support RNA splicing analysis using large RNA-seq datasets, we implemented the set
of tools and algorithms illustrated in Figure 2.1c. In the first step, the MAJIQ builder combines
transcript annotations and coverage from aligned RNA-seq experiments in order to build an
updated splicegraph for each gene which includes novel (unannotated) elements such as junctions,
retained introns, and exons. Several user-defined filters can be applied at this stage to exclude
junctions or retained introns which have low coverage or are not detected in enough samples
in user-defined sample groups. Notably, per-experiment coverage is saved separately so that
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it can be used in subsequent analyses without reprocessing aligned reads a second time (i.e.
incremental build). This feature is highly relevant for large studies with incremental releases,
such as ENCODE and GTEx, and also for individual lab projects where datasets or samples are
added as the project evolves.
In the second step of the pipeline, the MAJIQ quantifier is executed. As in the original
MAJIQ framework, splicing quantification is performed in units of LSVs. Briefly, an LSV
corresponds to a split in gene splicegraphs coming into or out of a reference exon. Each LSV
edge, corresponding to a splice junction or intron retention, is quantified in terms of its relative
inclusion (PSI, Ψ ∈ [0, 1]) or changes in its relative inclusion between two conditions (dPSI,
∆Ψ ∈ [−1, 1]). Given the junction spanning reads observed in each LSV, MAJIQ’s Bayesian
model results in a posterior distributions over the (unknown) inclusion level (P (Ψ)), or the
changes in inclusion levels between conditions (P (∆Ψ)). This model accounts not only for the
total number of reads but also for factors such as read distribution across genomic locations
and read stacks. Given its Bayesian framework, the model can also output the confidence in
inclusion change of at least C (P (|∆Ψ| > C )), or the expectation over the computed posterior
distributions (E [Ψ], E [∆Ψ]). In this work, we introduce two new algorithms within the MAJIQ
quantifier. The first involves how intron retention is quantified, allowing for much faster execution
with higher accuracy (see Methods). The second addition is the implementation of additional
test statistics, termed MAJIQ HET (heterogeneous). Conceptually, the original MAJIQ model
assumes a shared (hidden) PSI value for a given group of samples and accumulates evidence
(reads) across these samples to infer PSI. In contrast, MAJIQ HET quantifies PSI for each sample
separately and then applies robust rank-based test statistics (TNOM, InfoScore, or Mann-Whitney
U).
2.2.2. Performance evaluation
In order to assess MAJIQ HET, our new method for detecting differential splicing, we
performed a comprehensive comparison to an array of commonly used algorithms using both
synthetic and real data. We considered only algorithms capable of analyzing large datasets,
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including the original MAJIQ algorithm (upgraded with the v2 code-base to enable efficient data
processing), rMATS turbo (Shen et al., 2014), LeafCutter (Li et al., 2018), SUPPA2 (Trincado
et al., 2018), and Whippet (Sterne-Weiler et al., 2018). Figure 2.2a shows processing time and
memory when performing a multi-group, multi-sample comparison, typical for such datasets. In
this case, we perform all pairwise comparisons between 10 tissue groups, and the number of
samples in each group grows from 1 (10 total samples) to 6 (60 total samples). All algorithms are
able to process such large datasets using only 0.5-4 GB of memory, an amount readily available
on modern laptops. However, large differences exist in terms of running time, with SUPPA2
(55 hours) and Whippet (50 hours) taking substantially longer to analyze the larger dataset (6
samples per group, 60 total samples) compared to approximately 6 hours by rMATS, LeafCutter
and MAJIQ v2.
Next, we assessed the accuracy of all algorithms using a large-scale synthetic dataset
for comparing two tissue groups. This synthetic dataset, by far the largest of its kind to the
best of our knowledge, was constructed to be “realistic” such that each synthetic sample was
generated to mimic a real GTEx sample from either cerebellum or smooth muscle tissues (see
Methods). All methods were required to report changing AS events which pass the method’s
statistical significance test and inferred to exhibit a substantial splicing change of at least 20%
(see Methods). However, we note that since the various algorithms use significantly different
definitions of AS events it is hard to compare those directly. For example, LeafCutter defines
AS events as clusters of overlapping introns which may involve multiple 3’/5’ alternative splice
sites and skipped exons, while rMATS is limited to only classical AS events with two alternative
junctions. Thus, to facilitate a comparative analysis, we resorted to comparing the various
algorithms output at the gene rather than event level using the synthetic dataset shown in
Figure 2.2b. First, we found SUPPA2 consistently reported over 6,000 differentially spliced genes,
thousands more than any other method, while Whippet reported roughly 785 genes, significantly
fewer than the other methods which reported over 2,000 changing genes (Fig. 2b top bar
chart). Whippet, followed by rMATS, reported significantly more non-changing events. SUPPA2,
rMATS, and Whippet all exhibited high FDR ranging around 15-30%, with the former two also
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Figure 2.2: MAJIQ v2 performance evaluation using synthetic and real data. (a) Time (left)
and memory (right) consumption when analyzing multiple sample groups. Results shown are
for running all pairwise differential splicing analysis between 10 tissue groups from GTEx v8 as
the number of samples per group increases from 1 to 6 (x-axis). (b) Performance evaluation
for differential splicing calls using simulated GTEx cerebellum and skeletal muscle samples and
aggregated over genes (see main text and Methods). Metrics include the total number of genes
reported as changing (TOTAL-CHG) or non changing (TOTAL-NO-CHG) by each method, and
the associated FDR and FNR. Horizontal axis denotes the size of the groups. (c) Upset plot
based on the 10vs10 analysis shown in (b). The bars on top represent the overlap between genes
reported as differentially spliced by each method indicated below it. The bars and FPR values by
each method name on the left refer to genes reported only by that method. (cont.)
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Figure 2.2: (cont.) (d) Reproducibility ratio (RR) plots for real data, using GTEx cerebellum and
liver samples. Analysis here is based on each method’s reported list of splicing events (not genes)
and unique scoring approach. X-axis is the ranked number of events reported by each method
and Y-axis is the fraction of those events reproduced within the same number of top-ranking
events when repeating the analysis using a different set of samples from the same tissue groups.
The length of the line represents the total number of differentially splicing events reported by
each method (see Methods for details). RR graphs are shown for comparing group sizes of 3
(left), 15 (middle), and 50 (right). (e) Intra-to-Inter Ratio (IIR) results for GTEx samples as in
(d). IIR computes the ratio between the number of events reported as significantly changing
when comparing two sample groups of the same type (N No Signal column) and the number of
events reported as significantly changing when comparing groups of different types (here GTEx
liver and cerebellum samples as in (d)).

exhibiting high FNR over 40%. Both MAJIQ and MAJIQ HET consistently maintained a lower
false discovery rate compared to other algorithms (0.3%) and a low level of false negative rate
which was similar to that of LeafCutter. On small sets, for example when using 5 samples per
group, LeafCutter had a slightly lower FNR (2.5% vs 5.5% for HET), but MAJIQ exhibited lower
FDR (0.03% vs 0.8%) while still reporting overall 34% more genes as changing (2,337 vs 1,739)
and 6% more as non-changing (7,110 vs 6,713). It is also worth noting that the actual difference
in the number of changing AS events reported by MAJIQ and LeafCutter is significantly higher,
with 4,267 reported by MAJIQ vs. 2,169 by LeafCutter. This increased difference is mainly due
to the increased resolution of event definition by MAJIQ. Specifically, MAJIQ uses the local
splice variations formulation described above, while LeafCutter uses a definition of overlapping
intronic regions which give rise to coarser event definition and can be sensitive to the coverage
threshold used.
The significant differences between the methods described above raises the question how
the reported sets of differentially spliced genes overlap. Figure 2.2c illustrates the result of such
analysis when using 10 samples per group. Here, we looked at the intersection between different
methods at the gene level and when a set was unique to a method (i.e. the underlying events are
well defined) we also estimated the associated FPR. We found SUPPA2 reports a significantly
higher number of unique genes (1,777) as differentially spliced but over a quarter of those are
false positives. The next set sizes are those for LeafCutter (333), HET and SUPPA2 (288),
14

HET (230), and MAJIQ HET and PSI (214) with a FPR of 4% for the LeafCutter’s unique
set and close to 0 FPR for both MAJIQ’s algorithms unique sets. rMATS and Whippet report
significantly fewer unique genes with a high false positive rate of 62% and 79% respectively.
Next, we turned to assess performance on real GTEx data using several metrics. Here,
unlike the synthetic data analysis which focused on comparative evaluation at the gene level,
we focus on the actual AS events reported by each method. First, we used the reproducibility
ratio (RR) statistic as shown in Figure 2d. The RR plots follow a similar procedure to that of
irreproducible discovery rate (IDR) plots, used extensively to evaluate ChIP-seq peak callers (Li
et al., 2011; Vaquero-Garcia et al., 2016). Briefly, RR plots answer the following simple question:
given an algorithm A and a dataset D, if we rank all the events that algorithm A identifies as
differentially spliced (1, ... , NA ), how many would be reproduced if you repeat this with dataset
D 0 , comprised of similar experiments using biological or technical replicates? The RR(n) plot, as
shown in Figure 2.2d, is the fraction of those events that are reproduced (y-axis) as a function
of n ≤ NA (x-axis), with the overall reproducibility of differentially spliced events expressed as
RR(NA ) (far right point of each curve in Figure 2.2d). In our RR analysis using groups of size 3
to 50 GTEx samples each, we found both MAJIQ and MAJIQ HET compared favorably to the
other methods, but with the new HET algorithm exhibiting improved detection power resulting
in a higher number of AS events at the same reproducibility level.
The second statistic we used for evaluating performance on real data is the intra-to-inter
ratio (IIR) (Norton et al., 2018), which serves as a proxy for FDR on real data where the labels
are unknown. Specifically, IIR computes the ratio between the number of differentially spliced
events reported when comparing groups of the same condition (e.g. brain) and the number of
events reported for similar group sizes of different conditions (e.g. brain vs liver). In our work,
we found IIR to be a lower bound estimate of true FDR, though it lacks theoretical guarantees.
In the analysis shown in Figure 2.2e, we found IIR to behave similarly to FDR on synthetic
data with MAJIQ, MAJIQ HET, and LeafCutter exhibiting low IIR of 2%-6% even for small
group sets of 5 samples, while rMATS, SUPPA2, and Whippet had an IIR of 13%, 26% and
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46% respectively. However, unlike FDR on synthetic data, IIR dropped much more significantly,
hitting practically zero for all methods for large sample groups. This result is to be expected
since the IIR statistic compares sample groups of the same type, unlike the synthetic dataset
described above where different tissues are compared.
The last component we included for assessing different methods’ accuracy is a comparison
to PSI quantifications using triplicates of RT-PCR assays, the gold standard in the RNA field.
We previously produced over 100 such experiments from two different mouse tissues and showed
MAJIQ compared favorably to SUPPA and rMATS (Vaquero-Garcia et al., 2016; Norton et al.,
2018). Here, we extended this analysis to LeafCutter and found that MAJIQ’s quantifications
correlates significantly better with those of RT-PCR (see Fig. S2). We note that this analysis
for LeafCutter was possible since all events we tested were simple cassette exon skipping, but it
is not clear how to translate LeafCutter’s output to actual PSI in the general case.

2.3. Discussion
MAJIQ v2 is the culmination of continuous development of MAJIQ since its original
release in Vaquero-Garcia et al. (2016). The original MAJIQ, like many other algorithms, was
designed for comparing relatively small groups of RNA-seq experiments from biological replicates.
However, datasets nowadays can easily grow to hundreds and thousands of non-replicate samples.
The sheer size and heterogeneous nature of such data poses challenges that go beyond just
algorithmic efficiency. Additional challenges include the ability to capture but also simplify
novel and complex splicing variations, the ability to define subtypes over such complex splicing
events, and the ability to visualize and process such events and subtypes for downstream analysis.
MAJIQ v2 is the only algorithm, to the best of our knowledge, that supports such features
through efficient implementation of several algorithmic innovations we introduced either here
(the simplifier, incremental build) or the full paper (Vaquero-Garcia et al., 2021) (modulizer,
VOILA v2 visualization package). In addition, we perform extensive comparison of MAJIQ v2
to other algorithms and create a resource for reproducible algorithm comparison in the form of
both data and software package. In the full paper, my co-authors further demonstrate the utility

16

of the new splicing analysis features by performing a detailed analysis of differential splicing
between more than 2,300 samples from GTEx v8 brain subregions (Vaquero-Garcia et al., 2021).
This is also demonstrated in our analysis of clinically-accessible and inaccessible tissues (next
chapter).
The algorithmic contributions in this work include a new method to quantify de novo
intron retention, an incremental build, addition of the MAJIQ HET statistics which do not
assume a shared PSI between samples in a group, and the modulizer in VOILA. The resulting
new features enhance splicing analysis, especially on larger datasets. For example, MAJIQ’s
incremental build saves much of the processing needed when adding new samples to existing
repositories. Labs or centers can thus process data such as GTEx once, then efficiently add more
relevant samples as needed. Furthermore, as these datasets get larger, we also expect to see
more de novo junctions. These junctions increase the complexity of the splicegraph and the size
of splicing events considered. The MAJIQ simplifier enables users to more finely control how
this complexity enters the analysis.
With respect to performance, we showed MAJIQ v2 compares favorably to available
methods in terms of efficiency, accuracy on synthetic data, and reproducibility on real RNA-seq
data. Specifically, on synthetic data we found MAJIQ and LeafCutter were the only two tools that
simultaneously demonstrated both low FDR and FNR when identifying genes with differential
splicing. We note though that our usage of LeafCutter in this comparison included additional
filtering for ∆Ψ > 20% beyond the default p-value based filtering. This additional filtering was
added as we found that the default LeafCutter settings performed much worse (Vaquero-Garcia
et al., 2018). On real RNA-seq data from GTEx, MAJIQ’s reproducibility was consistently higher
than all other tools, particularly when comparing a small number of samples. When comparing
MAJIQ HET to MAJIQ dPSI (from Vaquero-Garcia et al. (2016)), we found both to have similar
reproducibility, but HET offered a significant increase in detection power. Finally, in terms of
efficiency, we found MAJIQ v2 performed similarly to the most efficient tools in both memory
and time. This is a notable achievement given that MAJIQ is the only tool amongst those that
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offers detection and quantification of de novo intron retention, a computationally expensive yet
important analysis as we discuss below.
The extensive evaluations we performed here serve not just to assess the specific tools
we included, but as a service for the community. First, we created the largest synthetic RNA-seq
dataset to date, with over 300 samples. In contrast to many other works, the data generated
here was based on real life GTEx samples. It also does not reflect MAJIQ’s model and was
based instead on transcript-based quantifications by other algorithms (RSEM). As such, we
would expect it to benefit tools that are built around a similar model (e.g. SUPPA). A second
contribution is the evaluation package we created, validations-tools. This package allows users
to not only reproduce our results but also to easily add future tools and repeat the analysis for
future developers or for anyone who wants to assess performance on their own unique dataset.
We highly recommend researchers and cores to take advantage of this as it is possible that on
a dataset with other characteristics the various algorithms would perform differently. Finally,
we note that the efforts to create reproducible results in genomics and specifically for tool
development are constantly ongoing. We previously documented in detail issues we identified
with using outdated software, software misuse, and lack of reproducibility that severely affected
MAJIQ and other software assessment (Vaquero-Garcia et al., 2018).
Finally, our improved pipelines allowed us to map splicing variations across heterogeneous
datasets of hundreds or thousands of experiments, as my co-authors demonstrate in the full
paper on GTEx subregions (Vaquero-Garcia et al., 2021) and in the analysis of adult and fetal
tissues described in the next chapter.

2.4. Methods
2.4.1. MAJIQ builder
In this subsection, we review how the MAJIQ builder prepares the structure and observations per experiment that are used for downstream splicing quantification as part of a scalable
and principled approach to splicing analysis of large numbers of experiments. We describe
the MAJIQ builder’s new approach for estimating intron read rates, which allows junction and
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intron coverage to be calculated once and reused efficiently for multiple analyses, unlike other
methods that quantify intron retention. We also describe the MAJIQ simplifier, which reduces
the complexity of the structural models of splicing used in quantification that especially arises
from the analysis of large and heterogeneous datasets.
MAJIQ encodes the set of all possible splicing changes for a gene in terms of a splicegraph.
A splicegraph is a graph-theoretic representation of a gene’s splicing decisions from one exon to
another, with exons as vertices and junctions and retained introns as distinct edges connecting
exons. The exons of each gene are non-overlapping genomic intervals. Each junction has a
source and target exon with a position within each exon, indicating the positions that are spliced
together when the junction is used. Retained introns are between adjacent exons and indicate
that intron retention between the exons is possible.
MAJIQ first constructs each gene’s splicegraph by parsing transcript annotations from
a GFF3 file. Exon boundaries and junctions from each transcript for a gene are combined in
order to produce the minimal splicegraph that includes each transcript’s annotated exons and
junctions, splitting exons by retained introns to ensure that each junction starts and ends in
different exons. MAJIQ then updates the splicegraph with novel junctions and introns found
from processing input RNA-seq experiments’ junction and intron coverage.
MAJIQ processes aligned input RNA-seq experiments to per-position junction and intron
coverage in the following way. First, MAJIQ identifies reads with split alignments. The genomic
coordinates of each split corresponds to a potential junction. Meanwhile, the coordinate of the
split on the aligned read is the junction’s “position” on the read. MAJIQ counts the number
of reads for each junction from each possible position. Afterwards, MAJIQ identifies reads
that contiguously intersect known or potential introns (i.e. reads that intersect the genomic
coordinates between adjacent exons without splits within the intron boundaries). If the intron
start is contained in the aligned read, the intron “position” is defined as for junctions (treating
the exon/intron boundary as a junction with zero length). For aligned reads intersecting the
intron but not the start, additional positions are defined by the genomic distances of the first
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positions of the aligned reads to the intron start. These additional positions per intron increase
the number of ways aligned reads can intersect introns in comparison to junctions. To adjust
for this and model intron read coverage similarly to junction read counts, MAJIQ aggregates
together adjacent intron positions to the equivalent number of possible positions per junction,
taking the mean number of reads per reduced positions.
MAJIQ uses the obtained junction and intron coverage to update the splicegraph in the
following way. Each potential junction is mapped to matching genes by prioritizing (1) genes
that already contain the junction (i.e. annotated junctions) over (2) genes where both junction
coordinates are within 400bp of an exon, which are prioritized over (3) genes where the junction
is contained within the gene boundaries. The input experiments are divided into user-defined
build groups. MAJIQ adds a novel junction to the splicegraph if there is sufficient evidence for
its inclusion in one of the build groups. This happens when the total number of reads and total
number of positions with at least one read exceeds the user-defined minimum number of reads
and positions in at least a minimum number of experiments. MAJIQ adds novel exons or adjusts
existing exon boundaries to accommodate the added novel junctions as previously described.
Potential introns are added to the splicegraph under similar criteria, and their boundaries are
adjusted or split to accommodate the adjusted or novel exon boundaries.
Since processed intron coverage is averaged over the entire original intronic region, we
can carry over the same coverage as an estimate for all resulting splicegraph introns, which are
contained in the original intron’s boundaries. In contrast, MAJIQ’s previous approach, which is
also used by most other tools that quantify intron retention, quantified intron coverage using
local counts of unsplit reads sharing the position of known junctions. These local counts must
be calculated using information from all processed experiments (for all novel junctions), which
requires samples to be reprocessed each time an analysis with different samples are performed.
MAJIQ’s new approach allows intron coverage to be processed once and used for multiple builds
with potentially different intron boundaries. This enables MAJIQ’s new incremental build feature,
which saves intermediate files with junction and intron coverage that can be calculated once
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and reused instead of BAM files for multiple builds. This reduces storage and time processing
experiments that are part of multiple analyses.
While MAJIQ uses raw totals of read rates and number of nonzero positions for adding
junctions and introns to the splicegraph, the MAJIQ builder performs additional modeling of
per-position read rates for use in quantification. First, we mask positions with zero coverage
and with outlier coverage. Outlier coverage is assessed under the observation that per-position
read rates generally follow a Poisson distribution. For each junction/position, we use all other
positions with nonzero coverage for that junction to estimate the Poisson rate parameter. Then,
MAJIQ calls any position with an extreme right-tailed p-value (default 10−7 ) under this model an
outlier and ignores its contribution to coverage for quantification. Second, we perform bootstrap
sampling of the total read rate over unmasked positions in order to model measurement error of
true read rates. Under the assumption that each unmasked position is identically distributed,
MAJIQ performs nonparametric sampling with replacement to draw from a distribution with
identical mean and variance as the observed positions (see Section 2.4.7). Since we assume that
our read rates are generally overdispersed relative to the Poisson distribution, MAJIQ replaces
nonparametric sampling with Poisson sampling when the nonparametric estimate of variance is
less than the mean (i.e. underdispersed).
MAJIQ performs quantification of splicing events modeled as LSVs, which are defined
by a splicegraph. A source (target) LSV is defined for an exon as a choice over the incoming
(outgoing) edges to (from) that exon from (to) a different exon. In general, only LSVs with at
least two edges are considered. MAJIQ builder prepares output files with raw and bootstrapped
coverage for each junction/intron in each LSV for quick use by downstream quantifiers.
We observed that builds from many build groups or with high coverage tend to have
increasingly complex splicegraphs and LSVs with many junctions. Many of these junctions are
often lowly used in all the samples but were included in the splicegraph because they had enough
raw reads and positions (noisy novel junctions) or are part of an unused annotated transcript.
This motivated the MAJIQ simplifier, which allows junctions and introns to be masked from the
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final splicegraph used for quantification. After the splicegraph is constructed using all input build
groups, MAJIQ calculates the ratio of the raw read rate for each junction/intron relative to the
other junctions/introns in each LSV. If a junction has consistently low coverage in each of the
build groups relative to the other choices in the two LSVs it can belong to, it is “simplified” and
removed from the final splicegraph. This reduces the complexity of the final splicegraph and
quantified LSVs, making output files smaller and downstream quantification more efficient.
In summary, the MAJIQ builder combines transcript annotations and input RNA-seq
experiments in order to build a splicegraph encoding all possible splicing events consistent with
both annotations and data and to prepare read coverage for quantification in terms of LSVs.
The MAJIQ builder’s new approach for estimating intron read rates allows junction and intron
coverage to be calculated once and reused as part of an incremental build for multiple analyses,
unlike other methods that quantify intron retention. The MAJIQ builder also introduces an
approach for simplifying the complexity that arises in splicing events when processing large
numbers of experiments. Overall, this allows the MAJIQ builder to produce structural models
of possible splicing events and read coverage for downstream quantification that scale to the
setting of large numbers of RNA-seq experiments.
2.4.2. MAJIQ quantifiers
MAJIQ provides three methods for quantifying RNA-seq experiments. MAJIQ PSI,
MAJIQ dPSI, and MAJIQ HET, which we introduce in this paper. MAJIQ PSI and dPSI,
which were previously described in Vaquero-Garcia et al. (2016), quantify groups of experiments
that are assumed to be replicates with a shared true value of PSI per group. MAJIQ PSI
estimates a posterior distribution of PSI (Ψ) for a single group, while MAJIQ dPSI compares
these distributions for two groups in order to estimate a posterior distribution for dPSI (∆Ψ).
MAJIQ HET compares two groups of samples but drops the replicate experiments assumption,
enabling analysis of more heterogeneous samples. Instead, experiments are quantified individually
and groups are compared under the assumption that the true values of PSI are identically
distributed between the two groups.
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All three pipelines share the same underlying machinery for inferring posterior distributions
for Ψ. Formally, Ψ for a junction in an LSV is defined as the fraction of expressed isoforms
using the junction out of all expressed isoforms containing the LSV. This fraction is not directly
observable. Instead, we observe the number of reads aligned rj to each junction j in the LSV. We
model each rj as a realization of a binomial distribution over the isoforms with probability Ψj :




rj ∼ Binomial 

X

rj , Ψj  .

(2.1)

j∈LSV

We take a Bayesian approach to integrate prior knowledge of Ψ, allowing for improved estimation
when there is low read coverage. This requires a prior distribution on Ψ. We previously observed
that most values of Ψ are nearly zero or one, which can be modeled using a generalization of
the Jeffrey’s prior for an LSV with J junctions:
1
1
Ψj ∼ Beta
,1 −
.
J
J




(2.2)

This prior is conjugate to the binomial likelihood, allowing for efficient closed-form estimation of
the posterior distribution of Ψj given the observed number of reads:


Ψj

n

rj0

0

: j ∈ LSV

o



1
1 X 0
r .
∼ Beta  + rj , 1 − +
J
J j 0 6=j j

(2.3)

Since MAJIQ build obtains bootstrap replicates of observed read rates, we perform this posterior
inference on each set of bootstrap replicate read rates to obtain an ensemble of posterior
distributions.
For MAJIQ PSI, we obtain this ensemble of posteriors for replicate experiments by
adding the observed read rates from the experiments that pass more stringent reads and position
thresholds than the builder. MAJIQ PSI treats the average of the posterior distributions as a
final distribution over Ψ. It reports point estimates of Ψ as the mean of this distribution (E [Ψ])
and saves a discretized version of the distribution for visualization in VOILA.
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MAJIQ dPSI takes this a step further by using the posterior distributions on Ψ1 , Ψ2 for
two groups in order to compute ∆Ψ = Ψ2 − Ψ1 between the two groups. We start by computing
the distribution of ∆Ψ under the assumption of independence of Ψ1 and Ψ2 by marginalizing
the product of their distributions:
Pind (∆Ψ) =

X

P (Ψ)1 P (Ψ)2 .

(2.4)

Ψ2 −Ψ1 =∆Ψ

We know that Ψ1 and Ψ2 are not independent, so we integrate our knowledge that ∆Ψ is usually
close to zero as a prior on ∆Ψ. Following our previous work, we formulate our prior Pprior (∆Ψ) as
a mixture of three components: (1) a spike around ∆Ψ = 0, (2) a broader centered distribution
around ∆Ψ = 0, and (3) a uniform slab. We determine our final posterior distribution on ∆Ψ
by adjusting Pind (∆Ψ) by the prior and renormalizing:
P (∆Ψ) ∝ Pind (∆Ψ) Pprior (∆Ψ) .

(2.5)

MAJIQ dPSI computes point estimates of ∆Ψ using the posterior mean of the distribution
(E [∆Ψ]) and identifies confidence of measured changes in inclusion as posterior probabilities
P (|∆Ψ| > C ).
MAJIQ HET takes a different approach for comparing inclusion between two groups of
experiments. MAJIQ HET drops the assumption of replicate experiments to consider heterogeneity
in Ψ between experiments within a group. Instead, MAJIQ HET assumes that the values of
Ψ per experiment in each of the groups come from the same distribution. We evaluate this
assumption using null hypothesis significance testing. Null hypothesis significance testing is
performed using one (or more) of four tests: (1) Welch’s two-sample t-test, (2) Mann-Whitney U
test, (3) Total Number of Mistakes (TNOM) test, and (4) InfoScore test. Welch’s two-sample t
test and Mann-Whitney U test are well-documented elsewhere (Welch, 1947; Mann and Whitney,
1947). Our implementation of Mann-Whitney U test computes exact p-values when there are
at most 64 experiments and computes asymptotic p-values using normal approximation with
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tie and continuity correction for larger samples. Meanwhile, the InfoScore and TNOM tests are
adapted from ScoreGenes (Barash et al., 2004). The TNOM test evaluates how well a single
threshold on PSI can discriminate between the observed values in the two groups. The Total
Number of Mistakes is the minimum number of misclassified observations under the best possible
thresholds. The distribution on TNOM when the distributions are equal are calculated using the
closed-form formula in Ben-Dor et al. (2002) to obtain p-values. Similarly, the InfoScore test
evaluates how well a single threshold discriminates between groups, but, instead of measuring
misclassifications directly, it identifies the threshold with the highest mutual information between
the threshold and the true group labels. MAJIQ HET uses the dynamic programming algorithm
in Ben-Dor et al. (2002) to evaluate the distribution of InfoScore under the null hypothesis in
order to obtain p-values. All four tests require observed values of Ψ per experiment, which is
not directly observed. MAJIQ HET accounts for variable uncertainty per experiment in our
estimations of Ψ by repeated sampling of Ψ from the posterior distributions of quantified samples.
MAJIQ HET computes the p-value for each repeated sample of Ψ over quantified experiments
and reports the 95th-percentile over the resulting p-values. These p-value quantiles are not
calibrated, so MAJIQ HET also computes p-values with the posterior means of Ψ. MAJIQ HET
also reports the median of the observed posterior means of Ψ for each group. These p-values
and the difference between the median observed posterior means are used together downstream
in VOILA for the identification of high-confidence differentially spliced LSVs.
2.4.3. Sample selection from GTEx
We selected from GTEx in the following way. We required all samples to have a RIN
score of greater than 6. For performance evaluation we chose to evaluate a comparison between
cerebellum and skeletal muscle. We randomly selected 150 samples from both tissues, excluding
the same donor from being selected in both tissues. Samples were downloaded as FASTQ or
as BAM and converted to FASTQ depending on when they were released. Samples that were
part of v7 are available on SRA, so they were downloaded using SRA Tools (v2.9.6) as FASTQ
files. New samples from the v8 release were only available as BAMs on the cloud, so they were
downloaded and converted to FASTQ using samtools (v1.9).
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2.4.4. Simulated RNA-seq as ground truth
We used the expression quantification data from the GTEx v8 release as the basis for our
simulations. Briefly, we downloaded publicly available gene- and transcript-level quantification
tables for GTEx v8 from the GTEx portal (https://www.gtexportal.org/home/datasets). To
match how the GTEx consortium performed these analyses, we downloaded the GRCh38 build of
the reference genome sequence and gene models from v26 of the GENCODE annotation.
We selected 300 samples from GTEx to serve as the basis for 300 simulated samples,
each real sample providing the expression distribution underlying one simulated sample (Table
S3). To run BEERS, we first need to prepare four configuration files that are customized for
the desired dataset: geneinfo, geneseq, intronseq, and feature quants. The geneinfo, genenseq,
and intronseq files define the structure and sequence information for each simulated transcript.
As a result, these three files are determined solely by the choice of reference genome build
and annotation. The feature quant files are specific to each individual sample and define a
distribution of transcript-level expression. First, we used the genome sequence and gene models
to create the geneinfo, geneseq, and intronseq files. Since the genome is fixed across all simulated
samples. We used the same set of these files to simulate all GTEx-derived samples. Next, we
extracted TPM values for each sample from the GTEx transcript quantification table and used
these distributions of TPM values to generate separate BEERS feature quant config files for each
simulated sample. Lastly, to determine the total number of reads to simulate for each sample,
we used the gene-level quantification file to count the total number of gene-mapping reads in
each GTEx sample.
To simulated strand-specific reads with uniform coverage across no errors, substitutions,
or intron retention events, we ran the BEERS simulator using the following command-line options: -strandspecific -outputfq -error 0 -subfreq 0 -indelfreq 0 -intronfreq
0 -palt 0 -fraglength 100,250,500.
We transformed ground-truth transcript abundances into ground-truth splicing quantifi-
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cations for each splicing quantification tool, taking into account the tools’ differing definitions of
splicing events. First, we defined ground-truth abundances for each exon or junction by adding
the abundances of all transcripts including the exon or junction. Then, for each tool, we adopted
their splicing event definitions, mapping the exon/junction abundances to compute their splicing
quantifications.
MAJIQ
MAJIQ reports splicing quantifications with respect to LSVs. Therefore, ground-truth
values for PSI were calculated by dividing the ground-truth abundance of each junction by the
sum of the ground-truth abundances for all junctions in each LSV.
rMATS
rMATS reports a different format file per event type. But since all of them are classical
binary event types, all can be reduced to two paths events, inclusion and exclusion. Each file
contains the exon that defines each of the ways, so we calculate the Ψgt as inclusion/(inclusion
+ exclusion) using the exon transcript combination to get the exons ground-truth abundances
for all junctions in each LSV.
LeafCutter
LeafCutter reports splicing quantifications with respect to intron clusters composed of
several junctions. Ground-truth values for LeafCutter’s splicing ratios were calculated using
ground-truth junction abundances, similar to MAJIQ.
SUPPA2
SUPPA2 reports classical events similarly to rMATS. So the approach we use here is
similar to that tool. The main difference is that SUPPA2 reports the junctions coordinate in
each one of the paths, so we use those junctions ground truth quantification to obtain the Ψgt
as inclusion / (inclusion + exclusion).
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Whippet
Whippet outputs a psi.gz that contains the psi quantification of an event. That PSI
is their formulation of the quantification from inclusion and exclusion paths. Differently to
SUPPA2 or rMATS, Whippet combines a set of junctions to define a path, emulating in that
way a transcript (or a portion of it). So, in order to find Ψgt of those paths, we look for those
transcripts that include all the junctions (and virtual junctions). We combine the expression of
those transcripts to find the Ψgt of each path.
2.4.5. RNA-seq sample preprocessing before splicing analysis
We aligned RNA-seq reads from real and simulated GTEx samples to the human genome
for splicing analysis with MAJIQ and other tools using the following procedure. Simulated GTEx
samples were generated as pairs of FASTQ files. We performed quality and adapter trimming on
each sample using TrimGalore (v0.4.5). Some tools require reads aligned to the genome. For
these tools, we used STAR (v2.5.3a) to perform a two-step gapped alignment of the trimmed
reads to the GRCh38 primary assembly with annotations from Ensembl release 94. Other tools
required transcript quantifications relative to annotated transcripts. For these tools, we used
Salmon (v0.14.0) using the trimmed samples to estimate transcript abundances.
2.4.6. Performance evaluations
We wrote a package of evaluation scripts, called validations-tools, in order to compare
MAJIQ in terms of speed, memory footprint, accuracy, and reproducibility for each one of the
following tools: rMATS, LeafCutter, SUPPA2, and Whippet. This package was written to allow
future users to not only reproduce our results but to easily add future tools and repeat these
kinds of analyses with different datasets.
We adjusted the tools parameters following recommendations by each tool’s authors.
Specific parameters are listed in Table S4. For these comparisons, we evaluated the methods’
computational efficiency and ability to identify splicing differences.
First, we evaluated computational efficiency of the different methods. We evaluated
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computational efficiency in terms of runtime and peak memory usage. Not all tools provide an
extensive log of their execution, so, in order to measure wall time and memory usage, we used
the output of ‘/usr/bin/time -v‘. We ran each method for all pairs comparisons between
10 groups with increasing sample sizes on an Ubuntu Linux environment with 32 cores (Intel
Xeon 2.7GHz and 64GB RAM).
Second, we evaluated the different methods’ performance in quantifying splicing differences on simulated and real datasets. On the simulated datasets, where we know ground-truth
differences in splicing between transcripts, we calculated true and false positive rates for the
identification of splicing differences by each method. However, on real datasets, where no
ground-truth is available, it is not possible to calculate true or false positive rates. Instead,
we evaluated two metrics, reproducibility ratio (RR) and intra-to-inter ratio (IIR), on real (and
simulated for comparison) data. The first metric, RR, measures the internal consistency of
differential splicing tools. This internal consistency is reflected in the assumption that each tool
should identify roughly the same events when repeating a comparison between two groups using
different samples. We quantify this by performing two such comparisons and computing the
fraction of the top n differentially-spliced events in the first comparison that are also in the
top n events of the second comparison. This produces a “reproducibility-ratio” curve, RR(n)
for the method as a function of the number of top events. If the first comparison yields N
“significant” events, RR(N) is called the reproducibility ratio. For the specific case of MAJIQ, we
note that in order to comparisons of LSV-type events more comparable to classic AS events such
as used by rMATS, we filtered out overlapping LSVs (i.e. those that share junctions) in order to
avoid double-counting classic AS events. For example, a classic exon-skipping event would have
matching source and target LSVs that overlap. However, we note that this filtering only reduces
NA but does not affect the reproducibility curves (apart from extending to a different value of NA )
(Fig. S7). Although reproducibility of a method on real data is a scientifically important goal, it
is not a sufficient goal because highly biased methods can be highly reproducible. To address this
limitation, the second metric, IIR, is based on the principle that comparisons between (inter-)
two groups should have many more significant events than comparisons within (intra-) a group.
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Furthermore, significant events within the group are likely false positives. This is quantified
by computing the ratio of the number of significant events from an intra-group comparison to
the number of significant events from an inter-group comparison. We evaluated these metrics
for each tool with varying sample sizes to identify which methods outperformed each other in
different settings.
Event-level evaluations
In these evaluations we check reproducibility and accuracy of reported differentially
spliced events by the various tools shown in Figure 2. As we describe in the main text, each
tool defines alternative splicing events differently so that direct comparison of the events or their
number between tools is not possible. Thus, when using real data each method was assessed by
its own set of reported events to compute reproducibility ratios (RR) and intra-to-inter ratio
(IIR) as in Figure 2d,e.
In contrast, when using GTEx based simulated data we do have the “ground truth”
(denoted “gt” below) for the abundance of each transcript. We thus use these values to summarize
Ψ and ∆Ψ observed in each method reported AS events and assess accuracy using the following
definitions:
• True Positive: max ∆Ψtool ≥ 20% and pvaluetool ≤ 0.05 and max ∆Ψgt ≥ 20%
• True Negative: max ∆Ψtool < 5% and pvaluetool > 0.05 and max ∆Ψgt < 5%
• False Positive: max ∆Ψtool ≥ 20% and pvaluetool ≤ 0.05 and max ∆Ψgt < 5%
• False Negative: max ∆Ψtool < 5% and pvaluetool > 0.05 and max ∆Ψgt ≥ 20%
• Ambiguous: all other cases (when either ∆Ψ ∈ [5%, 20%) or when ∆Ψ and pvalue reported
by the tool conflict),
where max is taken over all junctions/introns that belong to each AS event.
The above definitions were used to assess accuracy at the event level for each method,
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as shown in Figure S1, and also served as the base for gene level evaluations described below.
Gene-level evaluations
To facilitate more direct comparison between the different methods shown in Figure 2
we aggregated each tool AS events and their respective annotation as TP, TN, FP, and FN
as given above to assess gene level performance. Naturally, gene level labels of TP, TN, FP
and FN are defined based on the events they contain. The gene level labels are easy to define
as positive or negative when all AS events embedded in it are considered positive or negative
respectively. The problem arises when a gene has some of its events as false positives and false
negatives. In that case, we prioritize the labels according to the following order: FP, FN, TP,
TN. This means for example that an occurrence of a false positive event in a gene (according to
the method’s specific event definition) would be counted as a false positive gene even if some
other events were correctly labeled as true negative or even true positives. The rationale for this
prioritization is that (a) positive events are expected to be rare and (b) we care the most about
trying to validate or follow up on wrong hits (false positives) followed by missing true changes
(false negatives).
2.4.7. Procedure for bootstrapped readrates from per-position reads
MAJIQ’s bootstrapping procedure can be defined as follows. Without loss of generality,
consider a single junction. For each RNA-seq read aligned with a split for this junction, we define
the read’s position relative to the junction (or vice-versa) with a position i and count the number
of reads associated with each position, which we call Si .
These raw readrates include biases that we would like to correct for; in particular, we
define an explicit procedure for removing stacks by comparing the number of reads at each
position against a Poisson model using the observed readrates at all other positions, which results
in a set of stack-corrected nonzero readrates Ri for i ∈ {1, ... , P}, where P is the number of
nonzero positions after stack removal. These are the observed units for bootstrapping, so to
emphasize:
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Ri ≡# of RNA-seq reads for i-th position,
i ∈ {1, ... , P} .

(observed readrates)
(nonzero positions after stack removal)

Other methods typically sum directly over positions Ri (really Si since they generally
also ignore read stacks) to produce a total junction readrate for use in quantification:

R≡

P
X

Ri .

(observed total junction readrate)

i=1

Since we are unsatisfied with uncertainty/variance accounted for by directly using R, we
generate samples from a bootstrap distribution over the P nonzero positions.
If we make the assumption that we are given the number of nonzero positions P and
that the underlying readrate for each of these positions is independent and identically distributed
with finite mean E [Ri ] = µ and variance V [Ri ] = σ 2 , we can derive the mean and variance of
our observed total readrate:

E [R] =E

" P
X

#

Ri

i=1

=

P
X

E [Ri ]

i=1

=µP,
V [R] =Pσ 2 .

(observed total readrate mean)
(observed total readrate variance)

If we were able to take two samples for the observed total readrate (i.e. R and R 0 ), their
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difference has mean 0 and variance 2Pσ 2 .
We define our bootstrapping procedure over observed nonzero reads R1 , ... , RP to
^ R
^ 0 , ... such that the variance of the difference between
generate bootstrapped total reads R,
bootstrap samples would be equivalent to that of the difference between two samples from the
true distribution (i.e. 2Pσ 2 ). In order to do this, we take P − 1 samples from {R1 , ... , RP } with
replacement and scale their sum by P/(P − 1).
It is straightforward to see that the bootstrapped total readrate has the same mean as
the observed total readrate. In order to prove that the variance of the difference between two


sample matches, we note that the covariance Cov RZk , RZk 0



between any two draws from the

observed per-position readrates with Zi ∼ Uniform(P) is:




h



Cov RZk , RZk 0 =E (RZk − µ) RZk 0 − µ
h

i

i

=E RZk RZk 0 − µ2 .
. We note that E [Ri Rj ] = σ 2 δij + µ2 (where δij is the Kroencker delta). When k = k 0 , it follows
h

i

that E RZk RZk 0 = σ 2 + µ2 . Otherwise, the law of total expectation gives:
h

i

h h
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=
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(given k 6= k 0 )
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P

Combining the two cases, we have:
h

E RZk RZk 0
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1
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P
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(second moment sampled readrate)

Therefore,

 1
P −1 2
Cov RZk , RZk 0 = σ 2 + δkk 0
σ .
P
P

(covariance sampled readrate)

Thus, the variance of the bootstrapped total readrate is
^ =
V R
h i

P−1
X
P2
V
RZk
2
(P − 1)
k=1

"

#

=

P−1


X P−1
X
P2
Cov
R
,
R
Zk
Zk 0
(P − 1)2 k=1 k 0 =1

=

P−1
X P−1
X 1
P −1 2
P2
σ 2 + δkk 0
σ
2
(P − 1) k=1 k 0 =1 P
P

=2Pσ 2 .

(true bootstrap readrate variance)

But we want the variance of the difference between two samples from the bootstrap procedure.
So, we calculate the covariance between two distinct samples:
^ R
^0 =
Cov R,




P−1
X P−1
X 1
P2
σ2
(P − 1)2 k=1 k 0 =1 P

^
(covariance between samples of P)

=Pσ 2 .
Therefore, we find that:
^ −R
^ 0 =2V R
^ − 2 Cov R,
^ R
^0
V R
h

i

h i





=4Pσ 2 − 2Pσ 2
=2Pσ 2 .

(bootstrap total readrate variance as difference)

In practice, the observed nonzero positions can lead to a bootstrap distribution with
variance less than its mean (underdispersed). We generally expect readrates to follow a Poisson
or negative binomial (overdispersed) distribution, so in these cases, we fall back to parametric
bootstrapping with a Poisson distribution with mean µP. Otherwise, we use the nonparametric
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bootstrap sampling procedure as described above.
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CHAPTER 3
Mapping splicing variations in clinically accessible and nonaccessible tissues
3.1. Introduction
The previous chapter described how we built MAJIQ v2 to analyze large and heterogeneous
RNA-seq datasets as part of our goal of improving the molecular diagnosis of patients with
suspected Mendelian disorders. In this chapter, we use the MAJIQ v2 methodology to answer
the question of how tissue-specificity affects what splicing variations we can expect to capture in
the clinical setting.
As laboratories move to measuring the transcriptome directly with RNA-seq, one challenge
they face is tissue specificity. Tissue-specific expression is the most discussed complicating factor
of RNA-based analysis, as a gene must be expressed in the tissue to be studied (Cummings et al.,
2017; Gonorazky et al., 2019). Alternative splicing between tissues is less often addressed, and
further complicates analysis. If a tissue other than the tissue of clinical interest is tested, a gene
that is expressed in both tissues can still be spliced differently. Thus, splicing defects affecting
the tissue of clinical interest might not be realized in the tested tissue despite the gene being
expressed in both. Therefore, one tissue can be an adequate proxy for a gene’s splicing in a
different tissue only if it is both expressed and spliced similarly (Figure 3.1b).
Clinicians and researchers can only perform RNA-seq on tissues they have access to. In
the clinical setting, these tissues are typically limited to those from blood or skin biopsies: whole
blood, Epstein–Barr virus (EBV)-transformed lymphocytes, and fibroblasts. We refer to these
three as clinically accessible tissues (CATs). At the same time, laboratories are often interested
in pathology occurring in inaccessible tissues (non-CATs, e.g., brain, heart, etc.).
Several recent studies consider limitations of using RNA-seq from CATs for clinical
diagnosis. Frésard et al. (2019) demonstrate that RNA-seq in whole blood can make some
diagnoses in patients from diverse disease categories. However, Cummings et al. (2017) studying
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pre-mRNA splicing
pre-mRNA

RNA-seq from 56 tissues (n=801, ~15/tissue)
53 non-CATs (GTEx, HDBR, ...)

3 CATs (GTEx)

vs
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mature mRNA

Splicing identification and quantification
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- Δ protein sequence, localization
- premature termination codon
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No expression
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Identifying junctions/introns consistently...
No expression

used in non-CATs: Ψ > 50%
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Figure 3.1: Identification of splicing events inadequately represented by clinically accessible
tissues (CATs). (a) Different precursor mRNA (pre-mRNA) splicing decisions can have significant,
potentially pathogenic, functional consequences. (b) Splicing events in inaccessible tissues
(non-CATs) can only be adequately represented by accessible tissues as a proxy if the gene is
both expressed and similarly spliced. (c) We used MAJIQ on RNA-seq samples from 56 different
tissues to define and identify inadequately represented splicing events between inaccessible and
accessible tissues.
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a cohort of patients with neuromuscular disease, performed RNA-seq on skeletal muscle biopsies
collected as part of the clinical diagnostic workup motivated by low gene expression of many
known neuromuscular disease genes in whole blood and fibroblasts. Gonorazky et al. (2019)
further show that they can identify aberrant splicing in muscle that they would not detect
from fibroblasts from the same patients. While serving as an important proof of concept of
the limitations of RNA-seq with CATs in neuromuscular disease genes, these studies raise the
more general question: what are the limitations of RNA-seq in CATs across other non-CATs and
genes in general, and how can one quantify them? An answer to this question could inform the
selection of the best tissue to send for RNA-seq in clinical practice by evaluating the degree to
which each CAT faithfully represents splicing in genes and tissues of interest for different patient
phenotypes.
We address the question by considering splicing in nonaccessible versus accessible tissues
in terms of splicing events. We model splicing events as local splicing choices either starting or
ending at a single exon (the reference exon) in a given gene. These local choices involve splice
junctions or retained introns that are included in the gene’s transcripts. These splicing events
include constitutive splice junctions and local splicing variations (LSVs), which are splicing events
where the reference exons can be spliced to multiple RNA segments, thus allowing variation. We
identify and quantify splicing events from RNA-seq data using the MAJIQ v2 toolkit for splicing
detection, quantification, and visualization.
When using splicing in CATs as a proxy to splicing in some other tissue of interest, we
consider three possible scenarios or splicing event categories (Figure 3.1b): (1) the event is
unquantifiable in the CAT due to low gene expression and/or sequencing depth, (2) the event is
quantifiable but spliced differently, and (3) the event is quantifiable and not spliced differently.
We further focus on splicing events that are consistently included, meaning that they are similarly
quantified in nearly all samples for a given tissue type. Naturally, categorizing events into these
scenarios depends on the thresholds used to define them. Here, we define consistently spliced
events in non-CATs to be events with a junction or retained intron with Ψ > 50% in more
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than 85% of samples (Figure 3.1c). We emphasize finding the subset of these events that
correspond with either of the first two scenarios where splicing measured in a CAT inadequately
represents splicing in the non-CAT. We define these events as those that are unquantifiable or
have Ψ < 10% in more than 85% of a CAT’s samples.
In this work, we analyze 53 adult tissues in the Genotype-Tissue Expression Project
(GTEx) (GTEx Consortium et al., 2017) and 3 fetal tissues from the Human Developmental
Biology Resource (HDBR) (Lindsay et al., 2016) (cerebellum, cortex) and ArrayExpress accession
E-MTAB-7031 (Pervolaraki et al., 2018) (heart) (Figure 3.1c). We map all transcriptome
variations across these data sets, contrasting splicing between CATs and non-CATs. We make our
analyses accessible as an online resource, which we call MAJIQ-CAT (https://tools.biociphers.
org/majiq-cat). This online resource has been designed for clinicians and researchers interested in
obtaining patient RNA-seq in the context of Mendelian disease. With MAJIQ-CAT, these users
can explore how faithfully different CATs represent splicing in their specific genes and tissues of
interest, informing their choice of patient tissue to collect. Finally, we discuss implications for
RNA-seq in clinical practice and the need for alternative solutions for the genes and tissues that
are inadequately represented by CATs.

3.2. Materials and Methods
3.2.1. Sample selection criteria
We used RNA-seq data for samples from 56 different tissue types: 53 adult tissues and
3 fetal tissues. We obtained samples for all 53 adult tissue types from GTEx (dbGaP accession
phs000424). Meanwhile, we obtained samples for fetal cerebral cortex and cerebellum from
HDBR (ArrayExpress accession E-MTAB-4840), and we obtained samples for fetal heart from
ArrayExpress accession E-MTAB-7031.
All RNA-seq data have been previously described and were derived from tissues collected
ethically. For GTEx, tissues from deceased donors are not legally classified as human subjects
research under US Code of Federal Regulations Title 45, Part 46 (45 CFR 46) but were collected
under written or recorded verbal authorization from next of kin, while tissues collected from
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living donors were only included after full, written consent was obtained. HDBR is a tissue
bank regulated by the UK Human Tissue Authority, and samples in HDBR were collected with
appropriate maternal written consent and approval from a National Research Ethics Service
(NRES) Committee. The fetal heart samples were acquired with informed written parental
consent obtained from all subjects under approval of NHS Lothian, the University of Edinburgh
Research Governance Hope, and the University of Leeds Ethical Committee.
We restricted sample selection from each of these data sets/tissue types using available
metadata as follows. We restricted selection to unique donors per tissue type. This restriction
was relevant to both GTEx and HDBR, which include donors contributing multiple sample per
tissue type. Available HDBR metadata did not suggest criteria for preferring one sample over
another, so we restricted selection to the first available sample per donor. However, GTEx
metadata includes information on the number of megabases per sample, so we restricted selection
to the sample with the largest size. GTEx metadata also included further information that we
used; specifically, we further restricted selection to samples that (1) were hosted by National
Center for Biotechnology Information (NCBI), (2) had matched genome sequencing data, (3)
had an average spot length of 152bp, (4) were not flagged by GTEx as a sample to remove
(SMTORMVE), and (5) had an RNA integrity number (RIN) score greater than 6.
Given these restrictions, we selected up to 15 samples per tissue type for further analysis.
We chose 15 samples as the maximum number of samples per tissue group because preliminary
analysis using MAJIQ indicated that reproducibility for tissue-specific differential splicing analysis
saturates with around 15 samples in GTEx (data not shown). Consequently, when there were
more than 15 samples meeting the above criteria for a particular tissue type, we randomly selected
15 samples among them. For the other tissue types, we kept all samples meeting criteria for
further analysis.
3.2.2. Sample read alignment
We aligned RNA-seq reads from the selected samples to the human genome for splicing
analysis with MAJIQ using the following procedure. We downloaded selected samples as FASTQ
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files using SRA Tools (v2.9.6). We performed quality and adapter trimming on each sample
using TrimGalore (v0.4.5). We used STAR (v2.5.3a) to perform a two-step gapped alignment of
the trimmed reads to the GRCh38 primary assembly with annotations from Ensembl release 94.
3.2.3. Gene expression quantification
We quantified gene expression in each of the samples. We quantified transcript abundances in transcripts per million (TPM) using Salmon (v0.13.1) quasi-mapping on the trimmed
reads for each sample with a transcriptome built from Ensembl release 94 annotations. We
aggregated the quantifications to gene expression by taking the sum of abundances for the
transcripts associated with each gene.
3.2.4. Splicing identification and quantification using MAJIQ
First, we used MAJIQ v2 with Ensembl release 94 annotations to identify/model the set
of all possible annotated and de novo splicing events across our samples. We then quantified
these splicing events for each sample, considering an event to be quantifiable for a given sample if
it had at least one junction with at least ten supporting reads starting from at least three unique
positions. We estimated the percent spliced in (PSI or Ψ) for the junctions and retained introns
in each quantifiable splicing event. For the quantifiable LSVs, we used MAJIQ to estimate PSI.
Meanwhile, we assigned Ψ = 100% to the quantifiable constitutive junctions, as they were the
only choice for inclusion in their respective events.
Finally, we identified and filtered out ambiguous splicing events per sample. We defined
ambiguous splicing events as events containing junctions or retained introns that were in quantified
splicing events assigned to more than one gene. These ambiguous assignments occur because
of the presence of overlapping genes, especially combined with the unstranded nature of the
RNA-seq experiments we used. The resulting nonambiguous quantifications were used to identify
relevant consistent and tissue-specific differences between CATs and non-CATs.
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3.2.5. Identifying relevant splicing events
To determine the extent to which splicing in non-CATs is inadequately represented by
splicing in CATs, we first defined which splicing events for each non-CAT we would consider
changes in usage for. For each non-CAT, we consider the set of consistent splicing events, which
are splicing events with a junction or retained intron that is highly included in nearly all samples
for their tissue type. Specifically, we considered splicing events with a junction or retained intron
quantified as Ψ > 50% in more than 85% of the samples for each non-CAT.
We then evaluated how well splicing quantified in CATs reflected splicing in these
consistent splicing events. To do so, we identified the subset of these events for which usage in
CATs was consistently low or unquantified. Specifically, we identified which events were either
unquantifiable or had Ψ < 10% for the same junction or retained intron in more than 85% of the
samples for each CAT. We call these splicing events inadequately represented in their respective
CAT.
3.2.6. Analysis of genes with consistently used splicing events
We then aggregated information about these consistent and inadequately represented
splicing events to their respective genes for each tissue. That is, we determined which genes
had consistent splicing events in each non-CAT and the subset of these genes for which these
events were inadequately represented for each CAT. We evaluated gene expression for the
inadequately represented genes to assess how inadequately represented splicing related to low
gene expression versus tissue-specific alternative splicing. We also evaluated which of the
inadequately represented genes were annotated as disease-causing. We obtained our list of
disease-causing genes by combining annotations from ClinVar (gene annotations from the table
named “gene_condition_source:id”) and HGMD 2018.3 (inferred from variants classified as DM
(disease-causing mutation), the highest level of deleteriousness).
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3.2.7. Data access and software
Sequencing data used for this analysis are available in dbGaP under accession phs000424
and ArrayExpress under accessions E-MTAB-4840 and E-MTAB-7031. Software versions, resources, and specific parameters used are listed in Table S1 of Aicher et al. (2020). The analysis
was implemented for reproducible execution as a Snakemake pipeline. Links to source code for
the analysis and online resource, MAJIQ-CAT, are listed in Table S2 of Aicher et al. (2020) and
have been deposited to Zenodo.

3.3. Results
Our sample selection procedure yielded a data set with n = 801 RNA-seq samples for
53 non-CATs and 3 CATs. Seven hundred sixty-two samples came from GTEx, 30 fetal brain
samples came from HDBR, and 9 fetal heart samples came from E-MTAB-7031. We selected
and processed 15 samples for each tissue except for bladder, cervix (ectocervix and endocervix),
fetal heart, and fallopian tube, where we selected all available samples that met our criteria.
Across all samples, we identified a total of 239,406 quantifiable splicing events (124,909
LSVs and 114,497 constitutive junctions) in 25,494 genes. Per sample, we quantified a median
of 116,153 splicing events (65,481 LSVs and 50,719 constitutive junctions) in 12,872 genes.
We then identified and removed ambiguous splicing events with junctions or retained introns
associated with multiple genes, leaving a total of 223,590 splicing events (117,728 LSVs and
105,862 constitutive junctions) in 26,643 genes with a per-sample median of 107,174 splicing
events (60,591 LSVs and 46,825 constitutive junctions) in 12,049 genes.
Among quantified LSVs and constitutive junctions, we identified in each non-CAT a
median of 73,669 junctions or retained introns in 9,966 genes that were consistently used
(Figure 3.2a). Looking at these same events in CATs, we found that 27.7% were inadequately
represented in at least one CAT (3925 or 40.2% of genes); 4.4% were inadequately represented
by all CATs (609 or 6.3% of genes).
We compared the quantities of inadequately represented splicing per CAT and non43
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Figure 3.2: Mapping transcriptome variations identified in clinically accessible tissues (CATs) vs.
non-CATs. (a) Of an average of 9966 genes with consistently spliced events per non-CAT, 3925
(40.2%) were inadequately represented in at least one CAT, with 609 (6.3%) being inadequately
represented by all CATs. (b) The percentages of genes with consistently spliced events that were
inadequately represented over the 53 non-CATs were lowest in fibroblasts and highest in whole
blood. (c) The percentage of junctions/retained introns that were consistently used in at least
one non-CAT that were inadequately represented by each CAT was lowest in fibroblasts and
highest in whole blood.
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CAT. The median percentage of genes with consistently spliced events that were inadequately
represented across non-CATs was 10.8% for fibroblasts in comparison to 17.5% for EBVtransformed lymphocytes and 34.4% for whole blood (Figure 3.2b). The percentage was lowest
in fibroblasts and highest in whole blood for each non-CAT except for spleen, for which the
percentage was lowest in EBV-transformed lymphocytes. Considering all consistently spliced
junctions/retained introns across non-CATs, we found that the percentage of inadequately
represented splicing was also lowest in fibroblasts and highest in whole blood (Figure 3.2c).
We examined potential strategies for decreasing inadequately represented splicing compared with current practice. To evaluate the benefit of potentially acquiring and sequencing two
CATs instead of one, we quantified for each CAT the percentages of inadequately represented
events and genes that were not inadequately represented in the other two CATs (Figs. S3–S5
in Aicher et al. (2020)). We also considered how primary skin types, which are typically not
accepted by clinical laboratories for nondermatologic conditions, would perform as alternative
CATs by calculating their percentages of inadequately represented junctions and genes (Fig. S6
in Aicher et al. (2020)).
We further investigated the expression and pathogenicity of inadequately represented
genes. The maximum median gene expression across inadequately representing CATs was less
than 1 TPM in 52.1% of inadequately represented genes (Figure 3.3a). However, an average of
5.8% of inadequately represented genes per non-CAT (217 genes) are expressed with greater
than 10 TPM. Meanwhile, a median of 29.2% of inadequately represented genes per non-CAT
had variants annotated as disease-causing in either ClinVar or HGMD (Figure 3.3b).
To facilitate the interrogation of specific genes and splicing variations of interest by
clinicians, we developed MAJIQ-CAT (https://tools.biociphers.org/majiq-cat). MAJIQ-CAT is
an online resource that provides panels with which users can select genes and non-CATs to look
at how well CATs represent splicing across their genes of interest, both globally (Figure 3.4a) and
looking at individual splicing events in a specific gene (Figure 3.4b). Genes can be selected from
predefined lists of genes (e.g., from ClinVar, ClinGen, etc.) or custom lists provided by the user
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Figure 3.3: Expression and disease-gene relationship of inadequately represented genes. (a) The
majority of inadequately represented genes are lowly expressed (TPM < 1) in clinically accessible
tissues (CATs), but an average of 217 genes (5.8%) are well expressed (TPM > 10) in at least
one inadequately representing CAT. (b) An average of 29.2% of inadequately represented genes
are annotated as having disease-causing variants.
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either interactively or by uploading a text file. Non-CATs can be selected similarly. Changes to
these inputs automatically regenerate plots and tables describing the consistent and inadequately
represented genes. Individual genes can further be explored by clicking their names to load an
additional page that displays their tissue-specific gene expression and splicing events. For example,
if a laboratory was interested in studying intellectual disability as a phenotype, they could focus
on brain non-CATs and genes associated with the corresponding Human Phenotype Ontology
(HPO) term (HP:0001249), finding 1232 genes with consistent splicing in at least one of the
brain tissues (Figure 3.4a). They could further look for genes that are expressed but inadequately
represented by filtering the table by expression; in this example, setting a minimum of TPM >10
yields a list of 139 genes. Clicking into one of the resulting genes (e.g., MEF2C ) leads to another
page with comparisons of splicing in the CATs and the brain tissues, demonstrating where the
inadequately represented splicing events are and the distributions of PSI in each tissue for each
event (Figure 3.4b). We developed additional, more detailed example scenarios to demonstrate
how to use MAJIQ-CAT in the supplementary information of the published paper (Aicher et al.,
2020).

3.4. Discussion
In this study, we present a comprehensive analysis of RNA splicing events that consistently
occur in clinically inaccessible tissues, focusing on how corresponding events take place in clinically
accessible tissues. While clinicians and scientists are often interested in what takes place in the
inaccessible tissues as part of disease pathology, laboratories can only measure the accessible
tissues as a proxy. Thus, these results inform clinicians and scientists as to where RNA-seq is
limited, especially with respect to previously underappreciated tissue-specific splicing, and suggest
when specific clinically accessible tissues should be preferred over others or when alternative
approaches to clinical RNA-seq are needed. By making the results interactively accessible through
MAJIQ-CAT, we enable clinicians and scientists to more directly explore how these limitations
impact specific genes and tissues of interest to them.
Previous studies analyzing patient RNA-seq from CATs demonstrated that these data
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Figure 3.4: MAJIQ-CAT enables clinicians and scientists to explore inadequate representation
of splicing by clinically accessible tissues (CATs) in specific genes and tissues of interest. (a)
MAJIQ-CAT allows users to choose from predefined or custom gene sets and tissues (left) to
quantify and understand the user-specific relevant limitations of RNA-seq in different accessible
tissues (right). (b) Users can further explore individual genes for tissue-specific differences in
gene expression and splicing. Shown here is a closer look at the gene MEF2C, with a violin
plot of its expression in CATs and selected non-CATs (left) and violin plots of percent splicing
inclusion (PSI) for one of its inadequately represented splicing events (right). See main text for
more details.
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could be used to identify rare disease genes and variants from a variety of disease categories
(Kremer et al., 2017; Frésard et al., 2019). These studies demonstrate that although clinicians are
typically limited to using CATs for patient RNA-seq, RNA-seq in those tissues can still improve
the molecular diagnostic rate for suspected Mendelian disorders by identifying changes that were
not identified using exome or genome sequencing alone. Our study provides an orthogonal, but
related, result. Because we are typically limited to using CATs for patient RNA-seq, there are
splicing events found in disease-relevant tissues and genes that will consistently be a blind spot
in such studies.
Our study found that 40.2% of genes with consistent splicing events per non-CAT are
inadequately represented by at least one CAT. This implies that clinicians and scientists interested
in how one of the inadequately represented genes are spliced in the non-CAT in patients need
to be careful about which clinically accessible tissues they measure as a proxy because at least
one of the accessible tissues will not represent the splicing events well. We show that many
of these genes are considered disease-causing (29.2% of the inadequately represented genes);
thus, understanding these limitations is increasingly clinically relevant as RNA-seq enters clinical
practice.
Considering these 40.2% of genes with inadequately represented splicing, the majority
(52.1%) were associated with low gene expression (TPM < 1), as expected. However, we still
find that 217 genes per non-CAT are highly expressed (TPM > 10) but spliced differently in CATs.
The limitations of these genes for clinical RNA-seq would be missed by previous expression-first
analyses, highlighting the novelty and impact of our splicing-first analysis.
For the other 59.8% of genes, we note that splicing in CATs may still not always
adequately represent splicing in non-CATs. While they may not pass the stringent thresholds we
set to define inadequately represented splicing present in most samples for a CAT (Ψ < 10% or
unquantifiable in more than 85% of samples), splicing inclusion may take intermediate values or
be highly variable between samples. Furthermore, even for splicing variations that are similar
between tissues, they may still involve different tissue-specific regulation by different tissue-specific
49

factors. Thus, while we might expect variants in tissue-independent splicing sequence elements
(e.g., canonical splice sites) to impact the different tissues similarly, variants in tissue-specific
splicing enhancers or silencers could lead to tissue-specific defects that would not be represented
by CATs.
It is also important to note that the results described here are dependent on the limitations
and technical biases of current practices and technologies for poly-A selected RNA-seq. For
example, sequencing with greater depths or read lengths than is typically done in common
practice could potentially increase detection of lower-expressed genes/splicing events. Likewise,
alternative and/or future approaches for mRNA isolation or sequencing will differentially impact
detection of splicing across the genome. In particular, protocols including globin-depletion of
whole blood would likely improve its performance as a CAT because globin genes account for
the majority of expressed transcripts in GTEx whole blood. Since these data are not available
in GTEx, we plan to evaluate globin-depleted whole blood as a CAT for a future update to
MAJIQ-CAT. It will be important to re-evaluate differences in what we can detect between
tissues as emerging technologies, such as long-read sequencing, enter common practice and
replace current protocols for measuring clinical transcriptomes.
One important conclusion from the analysis performed here is that for the 3316 genes per
non-CAT that are inadequately represented by one or two CATs, at least one CAT offers a better
representation of the gene’s splicing than the others. Thus, our study implies that researchers
interested in one of these genes and tissues should have a preference for which clinically accessible
tissue to collect. Summarizing across all genes with consistent splicing, we found that fibroblasts
almost always had the lowest percentage of inadequately represented genes. Thus, our results
suggest that researchers interested in all genes and tissues equally should prefer collecting patient
fibroblasts if possible. However, clinicians and scientists are often interested in specific genes or
tissues relevant to a specific biological process. Our online resource, MAJIQ-CAT, will enable
clinicians, scientists, and laboratories to interactively explore which CATs are most relevant for
representing the biology they care about and which genes and splicing events are most affected.
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This work’s predictions about fibroblasts being a more appropriate CAT for clinical
analysis have since been corroborated by others in the literature. Murdock et al. (2021) analyzed
patient RNA-seq from both whole blood and fibroblasts. In solved cases with both tissues, they
were able to identify the putative causative defect in all the fibroblast samples but only half the
whole blood samples.
Another important conclusion of this study is that there are 609 genes per non-CAT that
are inadequately represented by all CATs. For these genes, using RNA-seq in any CAT as a proxy
would have many limitations for studying splicing. In these cases, alternative approaches are likely
necessary. One possible path forward is the use of in vitro differentiation or transdifferentiation
of CRISPR-iPSCs or patient-derived cells toward tissue types of interest. Gonorazky et al.
(2019) illustrated this possibility for transdifferentiated myotubes from patient fibroblasts as
an alternative to skeletal muscle biopsy, although how these results would translate to other,
more inaccessible, tissues remains to be explored. Another possible path forward is the use
of in silico models of splicing (Barash et al., 2010b,a; Xiong et al., 2015; Jha et al., 2017;
Zhang et al., 2019; Jaganathan et al., 2019; Cheng et al., 2019). Previous works in several labs
have developed models of tissue-specific splicing but do not directly train models on genetic
variants. Cheng et al. (2019) directly trains models to predict splicing changes using genetic
variants but does not account for tissue specificity. More recent (Cheng et al., 2021) and future
developments combining aspects of these models to produce predictions of tissue-specific splicing
as a consequence of genetic variants could help us understand potential splicing defects in those
genes where we do not have a good proxy. These alternative strategies could be combined
with other orthogonal approaches, including predicted variant pathogenicity, to further advance
detection of splicing variants in these inadequately represented genes.
In summary, in this study, we demonstrated and quantified the limitations of CATs to
serve as a proxy for non-CATs for RNA splicing measured by RNA-seq. We highlighted how
alternative splicing contributes to these limitations in addition to tissue-specific gene expression.
In addition, we developed and have made available an online resource, MAJIQ-CAT, that will
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allow clinicians and scientists to directly explore how these limitations affect specific genes and
tissues of interest. MAJIQ-CAT will be of particular use for determining tissues to study for genes
that are only inadequately represented in some but not all CATs. For the genes inadequately
represented by all CATs, future work on alternative approaches to estimate splicing defects in
patients will be necessary to improve clinical diagnoses.
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CHAPTER 4
MAJIQ v3 addresses limitations of MAJIQ v2
4.1. Introduction
Chapter 3 used MAJIQ v2 developed in Chapter 2 to answer the question of how tissuespecificity affects what splicing variations we can expect to capture in the clinical setting. With
actual analyses of RNA-seq data from patients with suspected Mendelian disorders (as discussed
in Chapter 5), we found that MAJIQ v2 lacked several features that we needed to accurately
and efficiently perform our analyses.
These missing features can be roughly divided into (1) better tools for comparing
genomic features identified (e.g., splicegraphs) from different groups of input experiments, (2)
valid intron retention coverage in rare cases of overlapping genes, and (3) additional measures
for quantification of PSI. Addressing these limitations required the development of MAJIQ v3.
In this chapter, I elaborate on these limitations, demonstrate how MAJIQ v3 addresses these
limitations, and show how MAJIQ v3 provides additional performance improvements integrating
features from MAJIQ v2 and MOCCASIN (Slaff et al., 2021).

4.2. Methods
4.2.1. MAJIQ incremental v3
In Chapter 2, we described incremental build (Figure 2.1c) as a new feature in MAJIQ
v2. Incremental build parses aligned reads from BAM files to create “SJ files” with coverage over
junctions and retained introns. These SJ files are used as input rather than BAM files to the
MAJIQ build step. By doing so, the BAM files for experiments used in splicing analysis only need
to be processed once, speeding up subsequent analyses. These SJ files are then organized into
independent build groups which, along with GFF3 transcriptome annotations, are processed all
at once in the MAJIQ v2 builder to simultaneously produce (1) a splicegraph, and (2) coverage
over LSVs over this splicegraph suitable for quantification (Figure 4.1a). In MAJIQ v2, this is
the only way of generating LSV coverage or splicegraphs.
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Figure 4.1: MAJIQ v3 extends MAJIQ v2 incremental build to splicegraphs and LSV coverage. (a)
The MAJIQ builder takes annotated transcripts (GFF3) and SJ coverage from input experiments
to produce (1) a splicegraph and (2) coverage over LSVs from that splicegraph. In MAJIQ v2,
these steps are coupled together. (b) In MAJIQ v3, coverage over LSVs can be produced directly
from an input splicegraph and SJ coverage. This improves parallelizability of splicing workflows
and allows incremental quantification of new experiments for direct comparison with previous
analyses. (c) In MAJIQ v3, new splicegraphs can be generated incrementally by combining 2 or
more input splicegraphs. The combined splicegraph is structurally equivalent to a splicegraph
built with the combined experiments used to create the input splicegraphs.
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MAJIQ v3 extends incremental build to LSV coverage and splicegraphs. Conceptually,
LSV coverage is a function of a splicegraph and coverage over junctions and retained introns
(Figure 4.1b). In this sense, the MAJIQ builder first identifies the splicegraph and then uses it to
define LSVs for coverage. MAJIQ v3 separates the MAJIQ builder into these two steps:
1. majiq-build update, which updates an input splicegraph (e.g., annotated splicegraph
from GFF3) with SJ coverage from RNA-seq experiments,
2. majiq-build psi-coverage, which outputs coverage over LSVs defined by input splicegraphs from input SJ coverage.
By separating these steps, generating LSV coverage over many samples can be parallelized not
only over multiple threads but over multiple machines on a cluster. Furthermore, LSV coverage
can be generated incrementally: that is, for new RNA-seq experiments that were not used to
define the input splicegraph. This incremental generation of LSV coverage is useful for the
scenario where a researcher has thousands of samples which have previously been quantified
with respect to a common set of LSVs. When the researcher obtains a few additional samples,
MAJIQ v3 can directly generate coverage for (and then quantify) these new samples against the
same set of LSVs. As a result, they can perform a quick comparison against the old dataset
without reprocessing any of the preexistent samples. In contrast, for previous versions of MAJIQ,
the approach would be to rebuild coverage over the combined set of samples and requantify all
of the thousands of samples.
However, the incremental coverage and quantifications from the new approach would be
over the original set of LSVs, rather than an updated set of LSVs that included evidence for novel
junctions and retained introns from the new samples. The splicegraph combining the original
and new input experiments can also be created incrementally without rerunning the MAJIQ
builder on all input experiments. MAJIQ v3 introduces the majiq-build combine command,
which takes two or more input splicegraphs to create a combined splicegraph (Figure 4.1). The
combined splicegraph is defined by:
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1. junctions: take the union of junctions found in each splicegraph, passing build/simplification
filters if they were passed in any of the inputs,
2. exons: identify annotated exons, then use splice sites from updated junctions to identify
novel exons and update existing exon boundaries,
3. retained introns: consider the intronic regions corresponding to annotated exon boundaries.
Mark each region as passing build/simplification filters if any of the input splicegraphs has
an intron overlapping the region that passed those filters. Then, define introns relative to
the new updated exon boundaries, passing build/simplification filters if they were passed
in the overlapping regions corresponding to annotated exon boundaries.
Combining input splicegraphs in this manner is equivalent to rerunning a build over the union of
the build groups from the input splicegraphs. So, rather than running the builder again over all
the input experiments, the researchers can instead build a splicegraph on just the new samples,
followed by running majiq-build combine with the old and new splicegraphs.
After introducing operations to combine multiple splicegraphs, one could imagine other
operations to manipulate and compare existing splicegraphs. For example, which introns and
junctions in the combined splicegraph are found only in the new experiments? Similarly, we may
expect that the combined splicegraph will have many of the same events as the old splicegraph.
Since we already have quantifications over the old events, can we identify which events are
shared vs not and perform quantifications only on the new/changed events? These questions
motivated creating additional operations over splicegraphs akin to an algebra over splicegraphs,
which we describe in Section 4.2.2.
4.2.2. Splicegraph algebra
MAJIQ v3 defines several operations on splicegraphs. One of these operations is
combining splicegraphs as described in the previous subsection. Additional operations include
identifying matched junctions, retained introns, and LSVs. These operations were motivated by
two goals we had for the clinical pipeline. First, we wanted MAJIQ to identify novel junctions and
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retained introns relative to control RNA-seq experiments (as well as annotated transcripts). In
contrast, MAJIQ v2 always defines “de novo” status of introns and junctions relative to annotated
transcripts. Second, when new samples (or cases) are added to an analysis (of controls), the
existing samples have already been quantified with respect to the old set of LSVs. We also
expect that most of these LSVs are unchanged in the new splicegraph. Rather than redundantly
storing and requantifying these same LSVs, identifying matched LSVs between the new and old
splicegraphs would permit producing coverage for (and subsequently quantifying) only the LSVs
unique to the new splicegraph.
Identifying matched junctions is straightforward: does the other splicegraph have a
junction for the same gene and coordinates. Identifying matched retained introns requires more
care. Exonic, and thus intronic coordinates, are updated between splicegraphs to match novel
junction splice sites. So, we cannot simply match intron coordinates. It is not enough to look for
overlapping intron coordinates, either. Extended exon boundaries and novel exons can mask or
split introns. So, we match introns from both splicegraphs to regions corresponding to boundaries
of annotated exons (as done for combining splicegraphs). Two introns are matched if they share
the same annotated intronic region. Finally, MAJIQ identifies matched events by searching for
events belonging to the same gene which have junctions and introns with the same coordinates.
In this case, we require intron coordinates to be identical because matched events are most
useful for thinking about quantifications. Different intron coordinates could lead to different
intron coverage and thus quantification.
Using these operations, MAJIQ v3 introduces the optional flag --annotated to its
quantification commands to identify novel transcriptomic features relative to another splicegraph.
to pass an additional splicegraph to its quantification commands. When used, MAJIQ accepts
an additional splicegraph as input and uses the above operations to identify which junctions,
retained introns, and events are novel relative to this splicegraph. Otherwise, MAJIQ v3 has
the same behavior as MAJIQ v2 and marks junctions and retained introns with de novo status
relative to the annotated transcripts. This could be used for the clinical setting by creating a

57

splicegraph including all RNA-seq samples except the patient of interest.
MAJIQ v3 also introduces the optional flag --ignore-from to its psi-coverage
command to omit LSVs found in another splicegraph. When used, MAJIQ accepts an additional
splicegraph as input and only outputs LSVs which are not found in this additional splicegraph.
This can be used to quantify splicing with respect to a previous analysis in two passes (Figure 4.2).

LSVs1:
SGcontrols

LSVs2:

( SGcontrols

SGcase )

SGcontrols

controls

case

Ψ

(1)

Ψ

(1)

Ψ

(2)

Ψ

(1)

controls

controls

case

case

Pass 1

Pass 2

Figure 4.2: MAJIQ v3 splicegraph algebra enables analyses to be performed in two passes. Figure
illustrates matrix of quantifications over experiments (columns) and LSVs (rows). Experiments
are divided into controls (blue) and a case (red). LSVs are quantified from the combined
splicegraph from the controls and case. That is, if SGcontrols is the splicegraph over controls
and SGcase is the splicegraph over the case, the analysis is performed on their combination
L
SGcontrols SGcase . The LSVs for the combined splicegraph can be partitioned into LSVs that are
the same in SGcontrols (purple) and those that are unique to their combination (green). Analysis
on these LSVs can be described as a first and second pass. Analyses sharing the same build
groups can be decomposed in this manner to compute quantifications on the first pass LSVs
only once.
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4.2.3. New model for retained intron coverage
MAJIQ v3 measures coverage over retained introns differently than MAJIQ v2. This
difference addresses artifacts in intron coverage around overlapping genes found in MAJIQ v2.
In MAJIQ v2, regions for intronic coverage are defined per gene. Each gene’s regions are defined
solely on the basis of the gene’s exons. As a result, regions from different genes on the same
contig can overlap, which leads to redundant time and space measuring intronic coverage for
overlapping regions. More critically, these regions can overlap each others’ exons. So, exonic
coverage from one gene can be artifactually counted to another gene’s introns. Figure 4.3a
illustrates how this happens in MAJIQ v2.
In contrast, MAJIQ v3 measures coverage over non-overlapping regions (per strand, if
the RNA-seq experiment is stranded) over each contig. The intronic regions from each gene are
combined, and the exonic regions for each region are subtracted, as illustrated in Figure 4.3b. This
excludes any exonic region from contributing to intronic coverage in a different gene. Additional
care is taken to identify intronic regions that belong to “annotated introns”. Annotated introns
are part of some annotated transcript’s exon that was split by junctions from other transcripts.
We identify regions that correspond to annotated introns so that they are not counted to novel
introns.
MAJIQ v3 measures coverage over these regions using the same procedure that MAJIQ
v2 uses for gene introns (as described in Section 2.4.1). This procedure bins together positions
for which aligned reads can overlap each region and counts overlapping unsplit reads per bin.
Then, MAJIQ maps this coverage back to introns in the following way. For each intron, MAJIQ
identifies the collection of these regions which overlap (in coordinates, strand, and annotation
status). MAJIQ takes the weighted average of number of reads, number of read bins with at
least one read, and bootstrapped coverage from each of the overlapping regions. The values
from each region are weighted by the number of read positions corresponding to the region (i.e.,
region length plus the maximum read length of the RNA-seq experiment, adjusted for minimum
overhang).
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a

b

Figure 4.3: MAJIQ v3 measures intron coverage over non-overlapping regions which exclude all
genes’ exons. (a) Diagram illustraing how MAJIQ v2 measures coverage in overlapping regions
which can overlap with each others’ exons. Squiggly lines show where exonic coverage from
other genes can lead to artifactual coverage. (b) MAJIQ v3 instead measures coverage over
non-overlapping regions which exclude all exons. Coverage regions are defined by excluding
all exonic regions and noting which regions originated from annotated introns. Coverage over
introns is determined by averaging overlapping regions.
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4.2.4. Corrected posterior standard deviation / variance
In order to identify single experiments as outliers for the clinical pipeline as described in
Chapter 5, we want to directly use estimates of uncertainty of the measured posterior distributions.
To enable this, MAJIQ v3 corrects how estimates of posterior distribution variance are calculated.
MAJIQ v2 attempts to calculate PSI posterior variance by the following approach. Recall
that MAJIQ estimates M bootstrap replicates of beta posterior distributions for Ψ, parameterized
by {(αm , βm )}M
m=1 . MAJIQ v2 calculates variance by discretizing Ψ into 40 equally-sized bins
over [0, 1], and setting the probability of each bin to the average probability of the bin over
bootstrap replicates. Then, MAJIQ v2 calculates variance with respect to the midpoints of the
bins, weighted by these probabilities.
There are many challenges with this procedure for estimating the posterior variance, for
which I will not elaborate further. However, if we imagine increasing the number of equally-sized
bins, we see that this is an approximation of a uniform mixture of beta distributions. The variance
of this distribution can be directly and exactly calculated much more efficiently.
This mixture distribution can be factored into its mixture components using the hidden
random variable Z ∼ Uniform ({1, ... , M}), indicating which of the M bootstrap replicate
posterior distributions Ψ is sampled from. Then, the conditional distribution of Ψ given Z is
Ψ|Z ∼ Beta(αZ , βZ ), where (αm , βm ) are the Beta distribution parameters for the m-th bootstrap
replicate’s posterior distribution. The law of total variance states that we can decompose the
variance of Ψ into the variance of a conditional expectation and the expectation of a conditional
variance. That is:
Var [Ψ] = Var [E [Ψ|Z ]] + E [Var [Ψ|Z ]] .
These conditional expectations and variances of a Beta-distributed random variable have closed
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form:
E [Ψ|Z = m] =
Var [Ψ|Z = m] =

αm
,
αm + βm
αm βm
.
(αm + βm )2 (1 + αm + βm )

So, the variance of Ψ is:
"

#

αZ
αZ βZ
Var [Ψ] = Var
+E
,
αZ + βZ
(αZ + βZ )2 (1 + αZ + βZ )




which can be computed by enumerating the means/variances of each component beta distribution
and numerically taking their variance/mean. This is faster and correctly calculates the variance
of the mixture of bootstrapped posterior distributions on PSI.
4.2.5. Approximate bootstrap coverage
MAJIQ v3 uses a smooth approximation to the uniform mixture of bootstrapped posteriors
for posterior quantiles and samples. Modeling PSI directly as a finite mixture distribution over
PSI causes challenges when total coverage at an LSV increases. As total coverage increases, the
uncertainty of each mixture component becomes vanishingly small. Since we only sample a finite
number of mixture components, the support of the actual mixture distribution becomes finite.
This leads to negative consequences when sampling or taking quantiles from the distribution.
Figure 4.4a,b shows mixture distribution with the same underlying mixture distribution means
but corresponding to small and high number of reads, showing how jagged the distribution can
become with increasing number of reads.
To resolve these difficulties, MAJIQ uses a smooth approximation of the mixture distribution when sampling (HET) and taking quantiles (CLIN). MAJIQ approximates the mixture
distribution with a single beta distribution, with parameters set to match the mixture distribution’s mean and variance. Figure 4.4c,d shows the smooth approximation’s probability density in
contrast to the original mixture.
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a

b

c

d

Ψ
Figure 4.4: MAJIQ v3 uses a smooth approximation to the uniform mixture of bootstrapped
posteriors for posterior quantiles and samples. (a) and (b) show the probability density function
of a mixture (in blue) of 30 beta distributions, each with the same mean, but corresponding to
LSV coverage of 50 vs 50,000 reads. (c) and (d) show MAJIQ v3’s smooth approximation of
this distribution (in orange) as a beta distribution with matching mean and variance, which is
used for posterior samples (HET) and quantiles (CLIN).
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4.2.6. MOCCASIN batch correction
MAJIQ v3 includes a rewritten implementation of MOCCASIN for batch correction
of coverage over LSVs. The new implementation is vectorized over junctions and bootstrap
replicates, resulting in significant performance improvements. It also takes advantage of changes
to underlying data structures (Section 4.2.7) to remove no longer necessary steps (e.g., matching
indexes for events, which are now consistently ordered) and to enable multithreaded and/or
distributed parallelism using Dask.
Similar to changes to MAJIQ build to enable two-pass analysis (Section 4.2.1), MAJIQ
v3’s implementation of MOCCASIN separates the different modeling and inference steps for both
unobserved confounders and coverage. Previously, MOCCASIN assumed that you had coverage
for all the LSVs you would ever want to work with (i.e., the coverage produced from v2’s builder).
So, MOCCASIN would be input with known factors and coverage and output updated coverage.
MAJIQ v3’s implementation of MOCCASIN is split into four steps:
1. majiq-moccasin factors-model: use coverage and matched known factors to a build
a model of unobserved confounding factors.
2. majiq-moccasin factors-infer: use coverage, matched known factors, and model of
unobserved confounding factors (from factors-model) to augment set of input factors
with inferred unobserved confounding factors. The model requires input coverage to be
over the same set of LSVs but works for new, previously unseen experiments.
3. majiq-moccasin coverage-model: use coverage and input factors to build a model of
coverage vs input factors.
4. majiq-moccasin coverage-infer: use coverage, input factors, and model of coverage
(from coverage-model) to generate updated coverage over LSVs removing variability
attributed to confounding factors. The model requires coverage to be over the same set of
LSVs but works for new, previously unseen experiments.
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4.2.7. Updated underlying data structures
Splicegraph, coverage and VOILA files were rewritten to improve performance, decrease
file sizes and enable parallelization with Dask. Redundant information (i.e. gene names, contig
names) is stored either by reference or computed as needed to decrease storage and memory
usage.
For SJ coverage, per-bin read counts are now kept in storage as a sparse matrix (most
junctions only have a few nonzero bins/positions). Bootstrapping is no longer stored and instead
computed on the fly as needed. This means that SJ coverage is now deterministic/reproducible
for the same input BAM file on different runs of MAJIQ. Splicegraphs exclude read counts, which
are split into separate splicegraph coverage files (produced by the sg-coverage command). This
keeps splicegraphs relatively small, and saves time spent to only assessing coverage when requested
rather than automatically for all input samples. Coverage over LSVs is stored redundantly, storing
the percentage of reads in the LSV to which a junction or intron was assigned in one array and
the total number of reads in the LSV repeated for each junction and intron. This is to enable
chunking the data over junctions/retained introns when the number of samples is large such
that it can no longer be loaded all at once in memory. LSVs are always stored in the same order.
4.2.8. Comparisons to MAJIQ v2
I randomly selected 20 samples from GTEx for performance comparisons between MAJIQ
v2 and MAJIQ v3. I considered three basic tasks: (1) creating SJ files from input BAM files, (2)
creating splicegraphs and LSV coverage for analysis from input SJ files, and (3) quantifying PSI
from output LSV coverage files. I measured runtime and memory usage with increasing numbers
of threads and samples. Performance comparisons were performed on a desktop running Ubuntu
20.04.2 LTS with Intel Xeon Gold 6238R CPU (2.20GHz) and 512GB RAM.
I also retrospectively analyzed runtimes for using SJ files to build a splicegraph, infer
coverage over LSVs, and quantifying PSI over the 762 samples from GTEx selected for the
analysis of clinically-accessible tissues described in Chapter 3. Build was performed with each
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tissue as its own build group, using the simplifier and setting min-experiments to 20%. We
compared runtimes building a splicegraph, inferring coverage, and quantifying PSI over each
individual sample.
We compared PSI quantifications from MAJIQ v3 vs MAJIQ v2 for a single skeletal
muscle sample from the above-described GTEx analysis (SRA accession SRR109847). We ignored
LSVs with half exon reference exons. To account for differences in LSV definitions, we compared
quantifications for individual junctions and retained introns as part of source vs target events.
We matched junctions by gene id and genomic coordinates. We also matched introns by gene
id and genomic coordinates, but we permitted matches to only one of the two coordinates to
small differences in exon definition. We compared inferred values of PSI, stratifying on whether
quantifications were for introns vs junctions and the total number of reads assigned to their LSV
in MAJIQ v3. We then explored specific quantifications where the tools gave different results to
understand if the changes were improvements.

4.3. Results
MAJIQ v3 introduces new features that further enable incremental analysis with large
numbers of samples. By decoupling how the MAJIQ builder produces splicegraphs and coverage
over LSVs, MAJIQ v3 enables adding a few samples at a time to a large analysis, analyzing their
combined set of splicing events while only needing to requantify events which have changed as
two passes for analysis.
We first compared speed and memory usage in generating SJ coverage for 20 RNA-seq
samples from GTEx using previously aligned BAM files (Figure 4.5). MAJIQ v3 was always
faster than MAJIQ v2 in creating SJ files with the same number of threads. With a single
thread, MAJIQ v3 created each SJ file an average of 17 ± 7 seconds faster than MAJIQ v2.
This difference increases with the number of threads. MAJIQ v2 runtime plateaus with around 4
threads, achieving a 2.0 ± 0.1 times speed up vs a single thread. In contrast, MAJIQ v3 with
4 threads is 4.5 ± 0.2 times faster than single-threaded v2 (4.0 ± 0.1 times vs single-threaded
v3) and does not plateau until around 9 threads (7.8 ± 0.8 times vs v2, 6.9 ± 0.7 times vs v3).
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Memory usage remains low in both MAJIQ v2 and v3 with increasing number of threads (less
than 1GB).
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Figure 4.5: MAJIQ v2 vs MAJIQ v3 runtime and memory usage when creating SJ files. (a)
Runtime and (b) maximum memory usage by MAJIQ v2 and MAJIQ v3 when creating SJ files
with increasing number of threads (horizontal axis). Measurements taken from 20 randomly
selected experiments from GTEx.
We then compared speed and memory usage in building splicegraphs and obtaining
coverage over LSVs. MAJIQ v2 requires these tasks to be run all together with a single thread.
In contrast, MAJIQ v3 supports doing these tasks in multiple steps with multiple threads by first
building a splicegraph and subsequently obtaining coverage over LSVs (which can be parallelized
over samples on multiple machines). Figure 4.6a-b compares runtime and memory usage for
running these steps sequentially with a single thread with increasing number of samples. These
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runtimes show a linear trend with increasing sample size. For MAJIQ v2, each experiment
contributes an average of 9.8 ± 0.1 seconds to the total runtime. For MAJIQ v3, each experiment
contributes an average of 1.78 ± 0.01 seconds. This is on top of baseline runtimes of 34 ± 1
seconds for MAJIQ v2 vs 8.0 ± 0.4 seconds. MAJIQ v3 performs these steps for 20 experiments
faster than MAJIQ v2 for a single experiment. If we extrapolated to the sample size of GTEx
(17,382 experiments), this would be a difference between 47.4 hours (v2) and 8.6 hours (v3).
These performance comparisons assume running these steps sequentially with a single thread.
MAJIQ v3 supports running these steps with multiple threads and in parallel. Since obtaining
coverage over LSVs is embarassingly parallel, we expect that MAJIQ v3 can complete these tasks
even faster (with respect to walltime) if given more resources.
We also compared speed and memory usage in quantifying PSI for individual experiments
to TSV files (Figure 4.7). MAJIQ v2 permits using multiple threads/processes for this step.
With a single thread, MAJIQ v2 takes an average of 230 ± 40 seconds to quantify each sample.
With 8 threads, MAJIQ v2 takes an average of 110 ± 20 seconds. In contrast, MAJIQ v3 with a
single thread takes an average of 8.5 ± 0.5 seconds to quantify each sample. Both MAJIQ v2
and MAJIQ v3 require less than 1GB of memory. MAJIQ v3 requires an average of 700 ± 50MB
of memory compared to 390 ± 60MB (1 thread) / 845 ± 1MB (8 threads) with MAJIQ v2.
We also retrospectively evaluated runtimes for the MAJIQ builder and MAJIQ PSI given
input SJ files for the 762 samples from GTEx described in Chapter 3. For MAJIQ v2, generating
the splicegraph over 53 tissues/build groups and generating coverage over LSVs for each sample
took place in a single step. MAJIQ v2 does not support running this step in parallel over multiple
threads. In contrast, MAJIQ v3 generated the combined splicegraph over 53 build groups by first
launching independent jobs to build tissue-specific splicegraphs. Then, MAJIQ (v3) combine was
used to generate a combined splicegraph. Afterwards, MAJIQ v3 launched 53 jobs in parallel for
each tissue to generate coverage over LSVs, each of which used 2 threads. MAJIQ v2 successfully
completed this step in 6 hours and 24 minutes. In contrast, for MAJIQ v3, the cluster walltime
(from when first job was launched to when last job was completed) was 2 minutes and 57 seconds.
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Figure 4.6: MAJIQ v2 vs MAJIQ v3 runtime and memory usage when creating building splicegraphs and LSV coverage. (a) Runtime and (b) maximum memory usage by MAJIQ v2 and
MAJIQ v3 when creating SJ files with increasing sample size (horizontal axis). Measurements
taken using up to the first 20 randomly selected experiments from GTEx with MAJIQ build
default parameters.
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Figure 4.7: MAJIQ v2 vs MAJIQ v3 runtime and memory usage when quantifying PSI. (a)
Runtime and (b) maximum memory usage by MAJIQ v2 and MAJIQ v3 when quantifying PSI
to TSV files with increasing number of threads (horizontal axis). Measurements taken from 20
randomly selected experiments from GTEx.
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The single-node walltime (adding walltimes for each job together) was 37 minutes and 56 seconds.
That is, over a single node, we observe a 10 times improvement in speed. Parallelizing over
a cluster, we observe a 131 times improvement in speed. Quantification of each independent
sample was performed on parallel jobs on the chop cluster for both MAJIQ v2 and MAJIQ v3.
For v2, the wall times were 37.5 minutes (cluster) and 2.5 days (single node). For v3, the wall
times were 1.5 minutes (cluster) and 14.3 minutes (single node). This amounts to a 25 times
improvement on our cluster and a 251 times improvement on a single node for quantifying PSI.
We compared the PSI quantifications from v2 and v3 from one of these GTEx samples
(skeletal muscle, accession SRR1098474). MAJIQ v2 quantified 77,271 LSVs, while MAJIQ v3
quantified 60,877 LSVs. From these LSVs, we identified 121,791 matched junction quantifications
and 27,042 matched intron quantifications (23,765 matching both coordinates, 3,277 matching
only one coordinate). Across these matched quantifications, only 3,893 (2.6%) differered in their
quantifications of PSI by more than 5%. Figure 4.8 plots these matched values of PSI, stratifying
with respect to total LSV coverage (from v3) and introns vs junctions. Most differences of
PSI greater than 5% come from LSVs with low coverage. For quantifications with even more
significant differences, we observed that introns tended to have higher values of PSI in MAJIQ
v2 and junctions tended to have lower values of PSI. Figure 4.9 provides an example where this
difference results from changes to intron retention coverage. Investigating the aligned reads
suggests that the higher value of PSI in the gene ERAP’s intron comes from the overlapping
exons of the gene CAST.

4.4. Discussion
We developed MAJIQ v3 to address methodological needs for the clinical pipeline.
One of these methodological needs was accurately quantifying uncertainty in the PSI posterior
distributions of an individual sample. To address this need, we updated how MAJIQ calculates
the variance of PSI posterior distributions to be more accurate and efficient. We further wanted
to extract specific quantiles from the the PSI posterior distributions, so we introduced new
methodology to make smooth approximations of the posterior distributions on which quantiles
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Figure 4.8: MAJIQ v3 vs MAJIQ v2 PSI comparison for introns/junctions and low to high
coverage. Points show matched observations of PSI from MAJIQ v2 and MAJIQ v3. The
horizontal/vertical axes represent PSI from MAJIQ v2/v3. Points are faceted into columns by
total LSV coverage (TLSV ) as measured by MAJIQ v3 and rows by whether the observation was
from a retained intron or junction. Retained introns are divided into matches with only one
coordinate (A) vs with both coordinates (B).
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GTEX-XGQ4-2326-SM-4AT53 (IGV)
[0 - 1114]

CAST (+)

ERAP1 (-)

chr5:96,758,000-96,782,200 (GRCh38)

Figure 4.9: MAJIQ v2 artifactually inflates intronic coverage in the gene ERAP due to overlapping
exons from the gene CAST. First panel is IGV view of RNA-seq reads for the GTEx sample GTEXXGQ4-2326-SM-4AT53 (SRR1098474). Second and third panels show MAJIQ splicegraphs for
the overlapping genes CAST and ERAP. For the left-most intron in ERAP1, IGV panel shows
coverage aligning with the exons of CAST. MAJIQ v2 assigns 49 reads to this intron (Ψ = 80%),
while MAJIQ v3 assigns 3 reads to this intron (Ψ = 23%).
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could be computed in a numerically stable way. Similarly, although introns in overlapping genes
are rare, we did not want our clinical pipeline to enrich for artifactually inflated intron coverage.
We addressed this need in v3 by changing how intron coverage is measured and assigned to
genes.
MAJIQ v3 is substantially more efficient than MAJIQ v2. We evaluated differences in
(1) extracting raw coverage from BAM files, (2) building splicegraphs and extracting coverage
over LSVs for analysis, and (3) quantifying PSI from individual experiments. For extracting
raw coverage, MAJIQ v3 was always faster than MAJIQ v2 with the same number of threads.
MAJIQ v3 also scaled better with increasing numbers of threads. For building splicegraphs and
extracting coverage over LSVs, MAJIQ v3 was over 5 times faster than MAJIQ v2 with a single
thread. In practice, this step can be performed even faster because MAJIQ v2 only supports this
step on a single thread while MAJIQ v3 supports processing LSV coverage in an embarassingly
parallel fashion over multiple threads and machines. For quantifying PSI, MAJIQ v3 was 27
times faster than MAJIQ v2. When analyzing the 762 samples described in Chapter 3 on the
CHOP cluster, MAJIQ v3 cluster walltimes were 94 times faster (single-node: 76 times faster)
than MAJIQ v2. Both MAJIQ v2 and v3 were efficient with memory, typically requiring less than
1GB of memory for each step.
These measured performance improvements do not illustrate how we could reuse analysis
results by analyzing data in two passes. While we describe here the methodology of MAJIQ v3’s
new operations on multiple splicegraphs, their impact in sharing common analyses over controls
and identifying novel junctions, retained introns, and events is best seen in the following chapter
in which we describe MAJIQ-CLIN.
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CHAPTER 5
MAJIQ CLIN identifies splicing aberrations from patient RNA-seq
5.1. Introduction
In this chapter, we use the methodology developed in Chapters 2 and 4 to address the
task described in Chapter 1; that is, to use RNA-seq on patient RNA-seq to improve molecular
diagnosis, focusing specifically on splice disrupting changes.
Previous studies have approached this problem for identifying splice disrupting changes
at the RNA-seq level by comparing patient samples to controls samples from similar tissue.
There are two general approaches that have been taken: (1) identifying novel junctions (not
found in controls) above some read threshold and (2) producing quantifications of inclusion of
all junctions in cases vs controls and identifying instances where cases are outliers relative to
controls. With respect to the first approach, Cummings et al. (2017) pioneered the first approach
on muscle samples, and Gonorazky et al. (2019) extended it by relaxing the requirement of novel
junctions by allowing them to be present in a few samples. With the second approach, different
studies have quantified splicing with respect to intron clusters (as from Leafcutter; Li et al.
(2018)) or junctions sharing a single 5’ or 3’ splice site. Kremer et al. (2017) and Jenkinson
et al. (2020) (LeafcutterMD) both use Leafcutter’s intron clusters for quantification, but identify
outliers differently using Dirichlet-multinomial likelihood ratio testing (Kremer et al., 2017) vs
beta-binomial tail probabilities (Jenkinson et al., 2020). Meanwhile, Frésard et al. (2019) and
Mertes et al. (2021) (FRASER) quantify inclusion with respect to shared 5’ or 3’ splice sites,
but create different statistical frameworks for identifying outliers using Z-scores (Frésard et al.,
2019) and beta-binomial tail probabilities (Mertes et al., 2021). These approaches identify a
need to correct for covariation between quantifications within each sample and either regress out
principal components on the quantifications directly (Frésard et al., 2019) or indirectly on the
beta binomial parameters using a linear autoencoder (Mertes et al., 2021). Mertes et al. (2021)
also evaluates retained introns by assessing unsplit read coverage at the same splice sites.
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Some of these approaches have been made more accessible as open source software
packages. The approach described in Jenkinson et al. (2020) was released as an update to
Leafcutter, with the new scripts called LeafcutterMD. The approach described in Mertes et al.
(2021) was released as the R package FRASER and as part of the DROP pipeline (Yépez et al.,
2021).
These packages are indifferent to whether they are structurally novel (as done by
Cummings et al. (2017)) and rely solely on quantified differences in splicing. Furthermore,
LeafcutterMD provides no way to correct for within-sample covariation. FRASER, while able
to perform correction due to unobserved confounders, does not permit specifying observed
confounding factors when known.
Here, we introduce MAJIQ-CLIN, a new pipeline to assess splicing in one or more individuals vs controls using the newly updated MAJIQ v3 toolkit for splicing detection, quantification,
and visualization. MAJIQ-CLIN uses MAJIQ v3’s algebra of splicegraphs to identify retained
introns, junctions and events that are structurally novel compared to controls, which can be
used to further filter or prioritize identified outliers. MAJIQ-CLIN also integrates MOCCASIN to
correct for between-sample covariation in PSI due not only to unobserved confounders but also
known confounders between samples. MAJIQ-CLIN implements an efficient two-pass approach
using MAJIQ v3’s algebra of splicegraphs in order to efficiently process each patient sample
against a shared set of external or leave-one-out controls, allowing for the vast majority of splicing
variations within controls to be quantified only once, while keeping the complexity of splicing
variations analyzed focused on individual patients.
In the remainder of this chapter, we describe how MAJIQ-CLIN works, demonstrate
how it compares favorably to existing methods, and apply it to patient data, re-identifying
previously-made diagnoses.
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5.2. Materials and Methods
MAJIQ-CLIN is a pipeline to identify splicing outliers in patient samples vs some set
of controls. First we define splicegraphs over patient cases and controls which allow us to (1)
define a set of shared LSVs over all patients that need to only be quantified once, (2) define
patient-specific LSVs, and (3) identify novel introns, junctions, and events for each patient.
Second, we use MOCCASIN to correct coverage over shared and patient-unique LSVs for observed
and unobserved confounders. Afterwards, we summarize population quantiles of PSI over these
LSVs in controls, and we compare how posterior quantiles of PSI in patient cases compare in
order to identify outlier events. We prioritize these events with respect to structural novelty and
the distance between extreme quantiles of the control and case distributions. In the remainder
of this section, I elaborate on how these steps are performed and describe how we compare the
results of this method to other tools.
5.2.1. Building splicegraphs for analysis
MAJIQ defines the set of junctions, retained introns, and LSVs which can be quantified
in terms of a splicegraph. Recall that MAJIQ builds splicegraphs by combining information from
transcript annotations and evidence from multiple build groups. For MAJIQ-CLIN, the final set
of patient LSVs for quantification is defined by combining a patient-specific build group and
build groups over controls. The build groups over controls pass/include retained introns and
junctions if they are found in enough experiments in the build group, while patient-specific build
groups pass/include retained introns and junctions if they are found in any experiment in the
build group.
For example, patient data from UDN (Murdock et al., 2021) includes cases from whole
blood and fibroblasts. We can use data from UDN as controls; however, we can further augment
the splicegraph with evidence from GTEx. For patients i and j with RNA-seq evidence from one
or both tissues, we would define patient-specific splicegraphs with the following build groups:
• Patient splicegraph i (with blood and fibroblast RNA-seq data)
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– patient-specific: patient i, blood; patient i, fibroblast
– controls: UDN whole blood
– controls: UDN fibroblasts
– controls: GTEx whole blood
– controls: GTEx fibroblasts
• Patient splicegraph j (with only fibroblast RNA-seq data)
– patient-specific: patient j, fibroblast
– controls: UDN whole blood
– controls: UDN fibroblasts
– controls: GTEx whole blood
– controls: GTEx fibroblasts
Each patient splicegraph has a unique set of LSVs because of their patient-specific
build group. However, we can build a single shared splicegraph excluding the patient-specific
build groups, which we call the “first-pass splicegraph.” When there are many more controls
than cases, we expect that this splicegraph shares nearly all the same LSVs as each of the
patient splicegraphs, such that there are only a few patient-specific LSVs. Then, analysis can be
performed in two passes: (1) once on LSVs from the first-pass splicegraph, and subsequently (2)
for each patient, analyze LSVs from the patient-specific splicegraph which were not found in the
first-pass splicegraph (and re-use results for the events shared with the first-pass splicegraph).
Frequently, the control build groups will include the patient itself (in the previous example,
patient i is found in both UDN whole blood and UDN fibroblasts, etc.). When this is the case,
we build a second patient-specific splicegraph explicitly excluding the patient from its component
build groups. This splicegraph is used to identify retained introns, junctions, and LSVs that are
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structurally novel for the patient.
5.2.2. PSI Coverage in two passes
First, we produce uncorrected PSI coverage with respect to the first-pass splicegraph
for each patient and the controls to which they will be compared (which may be different
than the controls used for building the splicegraph). Then, using this coverage and known
confounders, we use MOCCASIN to model unobserved confounders. We plot the percentage of
unexplained variance each learned unobserved confounder contributes to determine the number of
unknown confounders used in subsequent analysis. Then, using known and selected unobserved
confounders, we model and correct the PSI coverage using MOCCASIN. We also use these
unobserved factors from the first-pass PSI coverage to model and correct PSI coverage for the
LSVs unique to each patient-splicegraph as well.
5.2.3. Identifying and ranking outliers
We quantify PSI in cases and controls to identify and rank outliers using the corrected
coverage from Section 5.2.2. We identify events with junctions and retained introns that have a
gap between the extreme quantiles of the controls (from empirical distribution of PSI posterior
means) and each patient (from posterior distribution of PSI). We prioritize these events (and,
similarly, genes) with a gap in PSI first by whether they are novel to the patient (i.e., including
the patient as its own build group changes the structure of the event) and then by the size of
the largest gap between quantiles for the event.
The gaps in PSI between patients and controls are parameterized by a parameter α used
similarly to a “significance level” from two-sided null hypothesis tests. Specifically, we calculate
the quantiles corresponding to α/2 and 1 − α/2. Over controls, the quantiles are taken over the
empirical distribution of PSI posterior means. For each patient, the quantiles are taken over the
posterior distribution of PSI. When the intervals defined by these quantiles overlap, there is no
gap, otherwise, the gap is quantified as the difference in PSI between the closest quantiles. That
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is, if Ψ{controls,patient} (q) is the q-th quantile from the controls or patient distribution, we define
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Figure 5.1 provides a graphical illustration.
Controls
Patient posterior
Ψgap

0.0

0.2

0.4

Ψ
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Figure 5.1: MAJIQ outliers have a gap between extreme quantiles of controls and patient
distributions. For a retained intron or junction in an LSV, the gap between distributions Ψgap
(defined in Equation (5.1)) is the distance between extreme quantiles of the empirical distribution
of PSI posterior means from controls and the posterior distribution of PSI in the patient.
We only identify outliers for events which are quantifiable in the patient and over controls
(quantifiable in some minimum number of experiments in controls; default 75%). We also ignore
gaps where the difference in Ψ between the median of controls and patient posterior mean is
less than some minimum threshold (default 10%).
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5.2.4. Patient and control samples
We analyzed patient RNA-seq samples from three different datasets: (1) the Cummings
dataset (Cummings et al., 2017), (2) the Baralle dataset (unpublished), and (3) the UDN dataset
(Murdock et al., 2021). The Cummings and UDN datasets were downloaded from dbGaP, while
the Baralle dataset was shared with us by collaborators (Dr. Diana Baralle’s lab).
The Cummings dataset is composed of 53 RNA-seq samples from muscle biopsies of
patients with previously genetically undiagnosed rare muscle disorders. From these data and
matched exome or genome sequencing, Cummings et al. (2017) identified molecular diagnoses in
25 patients. Of these, we determined that 16 patients were candidates for RNA-first detection
as splicing outliers (the others: 4 allele-specific expression, 2 large structural variants, and 3
core-splice site variants identified from genetic sequencing but with insufficient coverage for
detection from RNA-seq). All samples were sequenced at the same site, so we treated these
data as if there were no confounders.
The Baralle dataset is composed of 55 RNA-seq samples from globin-depleted whole
blood from patients with suspected Mendelian disorders with diverse phenotypes. These data
were sequenced in three batches with 7, 16, and 32 samples each, so we used batch identity as a
confounder in our analyses.
The UDN dataset is composed of 833 RNA-seq samples from fibroblasts (n = 400), whole
blood (n = 380), and other tissues (n = 53) from patients with suspected Mendelian disorders
with diverse phenotypes and their affected/unaffected relatives. Murdock et al. (2021) describes
14 patients with causative variants which were identified by their RNA-first approach (using
DROP/FRASER plus additional filtering). Of these, data from 8 patients (11 samples from blood
and fibroblasts) were available as part of the UDN dataset. These data were sequenced with
four different sequencing instruments, so we analyzed each tissue separately using sequencing
instrument as a known confounder.
While batch correction and detection of outliers was limited to samples from within
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each individual dataset, we included samples with RIN score greater than 6 from GTEx v8 as
additional build groups for constructing splicegraphs. For the Cummings dataset, we included all
skeletal muscle samples as a build group. For the Baralle dataset, we included all GTEx whole
blood and EBV-transformed lymphocytes samples as build groups. For the UDN fibroblasts, we
included all GTEx cultured fibroblasts as a build group. For the UDN whole blood samples, we
included all GTEx whole blood samples as a build group.
5.2.5. Sample read alignment
We aligned RNA-seq reads from input samples following the same procedure as in
Chapter 3. That is, we aligned RNA-seq reads from samples to the human genome for splicing
analysis with MAJIQ using the following procedure. We performed quality and adapter trimming
on each sample using TrimGalore (v0.4.5). We used STAR (v2.5.3a) to perform a two-step
gapped alignment of the trimmed reads to the GRCh38 primary assembly with annotations from
Ensembl release 94.
5.2.6. Running other tools for splicing outliers
LeafcutterMD
We downloaded Leafcutter (commit hash 63b347a3) from Github. We followed the
standard LeafcutterMD pipeline as described in the online documentation: (1) count excised introns (junctions) using bam2junc.sh, (2) identify intron clusters and counts using
leafcutter_cluster.py (with maximum intron length of 500,000, required minimum reads in
a cluster as 50), (3) identify outlier clusters using leafcutterMD.R with default parameters.
Neither the LeafcutterMD paper (Jenkinson et al., 2020) nor the online documentation
gave any guidance as to how to translate cluster or intron p-values to prioritized clusters or
genes besides mentioning FDR correction. So, we adopted the following procedure and cutoffs
to consider outliers with respect to genes. We performed FDR adjustment on cluster p-values
using the Benjamini–Yekutieli procedure. We then identified outlier clusters using an FDR cutoff
of 10%. We prioritized clusters by adjusted p-values. We prioritized genes by mapping clusters
back to Ensembl release 94 annotations and scoring by the minimum adjusted p-value.
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FRASER
We used FRASER as part of the DROP pipeline. We installed DROP (v1.1.4) using
conda. We ran DROP/FRASER with Ensembl release 94 annotations using default parameters
(FDR cutoff of 10%, dPSI cutoff of 5%).
5.2.7. Comparison of splicing outlier tools
We evaluated MAJIQ-CLIN as compared to LeafcutterMD and FRASER in the following
ways. First, in order to compare the number of genes that would need to be reviewed for a
given patient, we compared the overall number of outliers the method produced for each sample.
Since clinical analysis is typically restricted to known disease-causing genes, we also filtered to
known disease causing genes (using gene lists from Murdock et al. (2021)). Since MAJIQ-CLIN
is particularly interested in splicing events which are novel to their patient-specific splicegraph,
we also considered gene counts when restricting to these structurally novel outliers. Second, for
the samples in the Cummings and UDN datasets that had been previously solved, we evaluated
(1) if each method identified the gene as having an outlier, and (2) how it prioritized the gene vs
others.

5.3. Results
We ran MAJIQ-CLIN, LeafcutterMD, and FRASER on the Cummings, Baralle, and UDN
datasets. We ran FRASER and LeafcutterMD with up to 4 threads, and MAJIQ-CLIN with up
to 2 threads on the CHOP cluster. MAJIQ-CLIN was the fastest tool for outlier prioritization in
each dataset (Table 5.1). We were unable to successfully run FRASER on the UDN dataset in
time for the submission of this dissertation. Running FRASER required allocating a surprising
amount of resources. The DROP pipeline repeatedly exceeded over 64GB RAM when counting
split and unsplit reads and was only able to finish when given 96GB RAM (twice what is required
for alignment). However, we were able to proceed through the pipeline far enough that we know
that the lower bound runtime is greater than that for MAJIQ-CLIN.
Without filtering on genes or structural novelty, MAJIQ-CLIN identifies more genes than
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Dataset

MAJIQ-CLIN

FRASER

LeafcutterMD

Cummings (n = 53)
Baralle (n = 55)
UDN-fibroblasts (n = 400)

4h09m
8h01m
3d,20h01m

8h56m
1d,19h00m
4d,12h02m (lower bound)

24h20m
23h18m
14d,10h15m

Table 5.1: MAJIQ-CLIN runs efficiently vs FRASER or LeafcutterMD. MAJIQ-CLIN was run with
up to 2 threads per job, while LeafcutterMD and FRASER used up to 4 threads. Runtimes with
MAJIQ-CLIN excludes processing GTEx alignments for coverage to compare processing same
number of alignments (and because they would typically have been preprocessed as part of an
incremental build). FRASER runtime for UDN-fibroblasts is a lower bound. We were unable to
finish rerunning FRASER in time for the submission of this dissertation due to high memory usage
(requiring over 64GB RAM). The reported time is for the counting, PSI calculation, and filtering
steps, plus six hours which had been run without completion towards fitting hyperparameters.
This excludes fitting the autoencoder, calculating p-values, and extracting results steps. For
comparison, these steps took an additional 1.5 hours for the Cummings dataset and 3 hours for
the Baralle dataset.
other methods, especially on the Baralle dataset (Figure 5.2). The number of outliers drops
significantly when restricted to known disease-causing genes (Figure 5.3). MAJIQ-CLIN still
identifies more genes than other methods. However, when MAJIQ-CLIN uses patient splicegraphs
to filter on novel LSVs, the number of outliers becomes less or comparable to the other methods.
For all of the previously solved cases from Cummings et al. (2017), Both MAJIQ-CLIN
and FRASER successfully identify outliers in the same genes as the 16 previously solved cases
from Cummings et al. (2017) amenable to splicing outlier analysis, while LeafcutterMD only
identifies the known gene in 6 of the cases (Figure 5.4). Focusing on disease-causing genes,
MAJIQ prioritizes the disease-causing gene first in all but two samples. In all samples, MAJIQ
identifies each gene as a novel event outlier. MAJIQ gives higher priority to the disease-causing
gene in all but one case, while FRASER prioritizes fewer other genes in all but 3 cases.
Looking at previously solved cases from the UDN dataset we can indirectly compare
MAJIQ-CLIN to FRASER because findings from Murdock et al. (2021) were made with FRASER.
We find that MAJIQ-CLIN identifies a change that FRASER did not. First, Table 2 of Murdock
et al. (2021) reports a patient with AP4M1 -associated spastic paraplegia which was identified
by outlier expression but not by splicing. MAJIQ-CLIN lists AP4M1 as the second highest
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Figure 5.2: Number of outlier genes (all) for each method on each dataset. MAJIQ-CLIN
identifies more outlier genes than other methods, especially on the Baralle dataset.
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Figure 5.3: Number of outlier disease genes for each method on each dataset. MAJIQ-CLIN
outlier disease genes (dodged left) can further be filtered to outlier novel event disease genes
(dodged right): that is, genes where at least one of the gaps in PSI was found in an LSV which
is structurally different when the patient is excluded from the splicegraph.
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Figure 5.4: MAJIQ-CLIN successfully prioritizes known disease genes from Cummings et al.
(2017). MAJIQ-CLIN and FRASER successfully solve all 16 cases from Cummings et al. (2017)
amenable to splicer outlier analysis. LeafcutterMD only solves 6 of 16 cases (38%).
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priority and specifically highlights the novel 52bp exon extension and intron retention which the
previous authors identified after following-up on the expression outlier. MAJIQ-CLIN gives priority
to the patients with disease-causing variants in RPL13 (rank 1), TBCK (rank 1), However,
MAJIQ-CLIN did not successfully identify an outlier in the patient with Au-Kline syndrome
(HNRNPK ), which the paper reports being identified by both expression and FRASER splicing
outlier analysis.

5.4. Discussion
We developed MAJIQ-CLIN as a pipeline to efficiently and accurately detect splicing
outliers in RNA-seq from patients with suspected Mendelian disorders. MAJIQ was substantially
faster than either LeafcutterMD or FRASER. FRASER was faster than LeafcutterMD on the
Cummings dataset but slower on the Baralle dataset. We were unable to finish running FRASER
on the UDN fibroblasts in time for submitting this dissertation. However, we were able to run
the FRASER pipeline far enough to show that the runtime is greater than that of MAJIQ-CLIN
by at least almost a day.
We were surprised by FRASER’s high demand for computational resources. Counting
split and unsplit reads with FRASER required over 64GB memory for experiments from UDN
fibroblasts. This is more than 100 times the memory than the equivalent step with MAJIQ (less
than 600MB, see Figure 4.5b).
With current thresholds, MAJIQ-CLIN reports more outliers than either LeafcutterMD or
FRASER. This means that without additional changes, clinicians using MAJIQ-CLIN would need
to spend more time reviewing these additional genes. For the case of LeafcutterMD, our analysis
on the Cummings dataset suggests that LeafcutterMD is too conservative, resulting in missed
diagnoses. On the other hand, FRASER manages to solve all the Cummings cases with fewer
prioritized genes. However, MAJIQ-CLIN consistently prioritized the known disease gene first or
second in all but two of the solved cases. For the Cummings dataset, MAJIQ-CLIN gave higher
priority to the disease gene than FRASER in all but one case. More work needs to be done to
further strengthen how MAJIQ-CLIN filters outliers, and the high priority given to known disease
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causing genes suggests there will be room to do so.
Our analysis is inconclusive about MAJIQ-CLIN vs FRASER. As we were unable to run
FRASER on all the other datasets, it is altogether possible that FRASER’s number of outliers
would be even higher. We note that all known disease genes were identified as novel events,
which suggests that we could use that as an additional hard filtering criteria. This would certainly
significantly drop the number of outliers to review, but at the potential expense of missing other
disease genes. The primary analysis being on the Cummings dataset raises the possibility of
selection bias because the original methodology used in Cummings et al. (2017) was dependent
entirely on novelty.
Our results on the UDN dataset are challenging to interpret. While identifying the
AP4M1 patient by splicing was encouraging (just as not identifying the HNRNPK patient by
splicing was the opposite), these differences could arise entirely from annotations (Murdock et al.
(2021) used GRCh37, we used GRCh38) or some other small detail. In future work, we will reach
out to the authors of DROP/FRASER to resolve our current computational challenges so we
can more directly compare MAJIQ-CLIN to FRASER on these data.
MAJIQ-CLIN compares favorably to LeafcutterMD and FRASER. In contrast to MAJIQCLIN and FRASER, LeafcutterMD does not quantify intron retention, nor does it correct
for the effect of confounding factors. These differences could contribute to LeafcutterMD’s
missed diagnoses on the Cummings dataset. MAJIQ-CLIN more readily permits analyzing
additional samples with its two pass approach. While FRASER and LeafcutterMD can reuse
their intermediate coverage files in subsequent analyses, there are several limitations. For
LeafcutterMD, new samples require reperforming “intron clustering” and subsequent modeling
steps over the entire dataset. For FRASER, the reusable intermediate coverage files only count
intron coverage at splice sites from the original dataset. If new samples introduce novel junctions
with novel splice sites, FRASER will be unable to quantify intron retention in competition with
these new junctions without reprocessing coverage from the original alignments. FRASER also
requires performing all modeling steps again from scratch. In contrast, MAJIQ-CLIN can reuse
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quantifications of controls and models of unobserved confounders/coverage over the original set
of first-pass LSVs. In this case, the only additional processing on controls that MAJIQ-CLIN
requires is to extract coverage from SJ files for the small set of second-pass LSVs the new sample
introduces, followed by modeling coverage and quantification.
Our analyses mostly focused on known disease-causing genes for the purposes of diagnosing patients with suspected Mendelian disorders. The machinery we developed in this chapter
for detecting outliers could be adapted in future work to other settings, including identifying
genes of unknown significance or neoantigens for cancer immunotherapy.
Overall, the analyses in this chapter demonstrate that MAJIQ-CLIN is capable of
accurately and efficiently detect disease-causing splicing outliers in patients with suspected
Mendelian disorders. In doing so, MAJIQ-CLIN can contribute to efforts to use RNA splicing to
improve molecular diagnosis rates, thereby helping provide more accurate prognoses and improved
clinical care for patients and their families.
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CHAPTER 6
Conclusions and future directions
6.1. Conclusions
This dissertation was motivated by the challenge of improving the molecular diagnostic
rate in patients with suspected Mendelian disorders. With exome sequencing or even genome
sequencing, less than half of these patients are expected to receive a moleclar diagnosis. In order
to address this challenge, we focused on methodology for detecting rare splicing aberrations in
bulk RNA-seq data from these patients. RNA-seq provides a functional readout of the impact of
genetic variation on gene expression and splicing. Thus, clinical RNA-seq provides an orthogonal
approach for identifying these rare splicing aberrations which we know are able to cause disease
but are challenging to identify with current methods from genetic sequence alone.
In Chapter 2, I describe my contribution as a co-first author to methods in MAJIQ v2
that enable us to accurately quantify splicing in large/heterogeneous populations as found from
human RNA-seq (Vaquero-Garcia et al., 2021). In Chapter 3, I used MAJIQ v2 to elucidate the
limitations of RNA-seq with clinically accessible tissues for detecting changes due to tissue-specific
expression and splicing (Aicher et al., 2020). However, as we began to apply MAJIQ v2 to
patient RNA-seq, informed by our analyses in Chapter 3, it became clear that MAJIQ v2 would
be insufficient due to challenges with rare artifacts in intron retention quantification and the
need to further minimize repeated work in analyzing control samples. Thus, in Chapter 4, I
describe how I developed MAJIQ v3 to address these issues. Finally, in Chapter 5, I describe the
methodology I built up on the lessons from these previous chapters to identify splicing aberrations
from patient RNA-seq samples and show that it compares favorably to previous tools.

6.2. Future directions
While the work presented here in this dissertation contributes to addressing the challenge
of improving the molecular diagnostic rate for patients with suspected Mendelian disorders, as
well as to how we can model and quantify splicing in general, there is still more work to be done.
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In the remainder of this chapter, I describe potential future directions.
This dissertation was focused on observed changes in RNA splicing from bulk RNA-seq as a
signal for improving the molecular diagnostic rate. One avenue for future work could be extending
the tools developed for splicing in MAJIQ to detect other transcriptomic aberrations. While
expression outliers or allele-specific outliers have well-established methods such as OUTRIDER
(Brechtmann et al., 2018) and ANEVA-DOT (Mohammadi et al., 2019), the changes they look
for are not well-suited for analysis with MAJIQ. However, Cummings et al. (2017) suggests that
RNA-seq could also be used to help detect structural variants. They describe a few patients
where plotting read coverage over the exons of DMD shows a qualitative decrease in coverage
at the 3’ of the genes consistent with large inversions intersecting the gene which were later
confirmed by genome sequencing. Figure 6.1 shows how total LSV coverage measured by MAJIQ
can be used to reproduce Fig S8E from Cummings et al. (2017). Future work could develop
tests to identify outliers in coverage across larger scale splicing modules or entire genes.
Modeling coverage across the body of a gene, as described in the previous paragraph,
relates to more general further improvements to how MAJIQ quantifies changes within a gene.
MAJIQ currently focuses on coverage from split reads and coverage aligned to intronic regions.
The approach to intron retention coverage introduced in MAJIQ v3 could easily be extended
to assess coverage more generally across genes, split by annotated and novel splice sites. This
could strengthen the analyses described in the previous paragraph. Furthermore, one weakness
of MAJIQ is its difficulty quantifying events with novel exitrons (that is, junctions that start and
end in the same exon). Wai et al. (2020) describes a patient case where the putative causal
splicing change involved an exitron; as a result, our clinical pipeline would likely fail on this
case. MAJIQ’s difficulty with exitrons arises precisely because the incremental coverage MAJIQ
measures excludes exons, so MAJIQ is unable to comment on intronic coverage underneath
the exitron without reprocessing input alignments. Exon coverage could also improve detection
and quantification of other relevant changes, including alternative transcript starts/ends, into
which MAJIQ currently provides less insight. As a result, expanding how MAJIQ processes read

91

Patient C2

DMD (contig=X, gene_id=gene:ENSG00000198947)
10
5
0

Patient N25 (control)

Patient C4

40
20

0
400
300
200
100
0

3.10

3.15

3.20

Genomic position

3.25

3.30

1e7

Figure 6.1: MAJIQ could be used to study structural changes in coverage across the body of
genes. The plots show total coverage in LSVs across DMD in patients where structural variants
overlapping DMD were identified as causal (C2, C4) and a representative control (N25) (as
previously described in Cummings et al. (2017), Fig S8E).
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coverage in exons to enable the quantification of additional transcriptomic features is a promising
avenue of future work.
Future work could also involve adopting new technologies such as long-read RNA
sequencing. Long-read RNA sequencing could be used to observe larger structural variants and
phasing of coordinated splicing. However, MAJIQ is specifically designed for analyzing short-read
RNA-seq. Future work could be directed towards adapting MAJIQ for modeling and analyzing
long-read RNA-seq data, followed by subsequent application of the methodology to patients with
suspected Mendelian disorders.
Finally, the analysis in Chapter 3 showed that over 6% of consistently spliced genes
in various clinically-inaccessible tissues would not be adequately represented when measuring
splicing in clinically-accessible tissues. These genes are a potential blind spot of the clinical
pipeline developed in Chapter 5. Future work should be done developing “DNA-first” approaches
to predict tissue-specific splicing defects from rare genetic variants to complement the “RNA-first”
approaches described in this dissertation. These approaches could use recent advances in machine
learning from natural language processing and computer vision to advance on previously published
methods for splicing predictions (e.g., Table 1.1). In addition to building prediction models on
sequence alone, future models could integrate splicing quantifications from accessible tissues.
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